ISPOR Glasgow

ISPOR

ISPOR 20th Annual European Congress

4-8 NOVEMBER 2017 SCOTTISH EVENT CAMPUS (SEC) GLASGOW, SCOTLAND

Photo credit: University of Glasgow

The Evolution of Value in Health Care PROGRAM AND SCHEDULE OF EVENTS


www.ispor.org



About ISPOR

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is the leading global scientific and educational organization for health economics and outcomes research (HEOR). ISPOR's mission is to promote HEOR excellence to improve decision making for health globally.

ISPOR Strategic Pillars



ISPOR Membership

ISPOR has a 20+ year legacy as an unbiased organization of more than 20,000 individual and chapter members. ISPOR promotes HEOR excellence through its:

- Scientific meetings and conferences
- MEDLINE®/PubMed-indexed journals
- Educational programs
- Roundtables, councils, and collaborative alliances
- Online tools
- Scientific and health policy groups
- Regional consortia, networks, and chapters
- Dialogue with payers and health care decision makers

Additional information on ISPOR and membership benefits can be found at **www.ispor.org**.

ISPOR 20th Annual European Congress

The Evolution of Value in Health Care



TABLE OF CONTENTS

Table of Contents

Congress Program Committee	5
Event Sponsors	6
Plenary Sessions	7
Schedule of Events. Saturday, 4 November Sunday, 5 November Monday, 6 November Tuesday, 7 November Wednesday, 8 November	9 12 15 21
Invitational Group Meetings	31
Poster Overview	34
Exhibit Program Overview	35
Exhibitor Listing	36
Exhibit/Poster Hall Floor Plan	37
Key Congress Information	39
Conference Rooms Floor Plan	40



We are advancing peri- and post-approval research.



30+ Years of Experience

Epidemiology · Health Economics · Interventional Studies Real-World Evidence · Patient-Centered Research · Evalytica[®] Pragmatic / Adaptive Trials · Modeling and Meta Analysis Market Access · Medical Writing

www.evidera.com

www.evalytica.com







Congress Program Committee

ISPOR thanks the Congress Program Committee for its contributions in developing the scientific community's leading HEOR program.

PROGRAM COMMITTEE CO-CHAIRS

Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands



Briggs

Franken

IJzerman

RESEARCH REVIEW COMMITTEE CO-CHAIRS

Margreet G. Franken, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands

Rok Hren, PhD, University of Ljubljana, Ljubljana, Slovenia

Andrea Manca, University of York, Heslington, York, UK

Ursula Rochau, MD, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

René Allard, PhD, Grünenthal GmbH, Aachen, Germany

Jan Geissler, Leukemia Patient Advocates Foundation, Patvocates, and European Patients' Academy (EUPATI), Munich, Germany

Camilla Palmhoj Nielsen, PhD, DEFACTUM, Aarhus N, Denmark

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Raquel Aguiar-Ibáñez, MSc, MSD, Hoddesdon, UK Martin Scott, MSc, Numerus Ltd., Tubingen, Germany Allan Wailoo, PhD, University of Sheffield and NICE Decision Support Unit, Sheffield, UK





Hren



Manca

Geissler

Nielsen



Aguiar-

Ibáñez



Scott



Wailoo

Rochau

Thank You to Our Event Sponsors



Plenary Sessions Featured at ISPOR Glasgow

FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

There now is a wide consensus that health care products and services should be priced in relation to the additional value they produce. While cost-effectiveness analysis explicitly assumes allocation of resources based on added societal value, practitioners and health care policy makers in European institutions now increasingly promote value-based health care (VBHC) as a more holistic, patientcentered understanding of value. Although VBHC seems well aligned with cost-effectiveness analysis, there are several fundamental differences. Where VBHC is embraced by health care practitioners and hospital administrators because of its focus on patient value over the entire care pathways instead

of single interventions, it lacks an operational definition of value in relation to cost. Another difference is that outcomes in VBHC are disease-specific, which implies they cannot be used for societal resource allocation decisions. This plenary session will therefore introduce VBHC in more general terms from a clinical and hospital perspective, and then will specifically discuss the challenges and main differences with costeffectiveness analysis from an industrial, health economics, and patient perspective.

Moderator: Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands Speakers: Peter Naredi, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; Luke Slawomirski, Organisation for Economic Co-operation and Development (OECD), Paris, France; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and European Society for Medical Oncology (ESMO), Uppsala, Sweden; Jason Arora, MD, MPH, Medtronic, Watford, UK

SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?

Health technology assessment (HTA) processes vary across jurisdictions. Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands), others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria). In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions. However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a "perfect HTA process" that can serve as the benchmark for other countries to adopt or adapt? This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated and the speakers will present different perspectives on evaluating the value of HTA processes.

Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Speakers: Susan Guthrie, PhD, MSci, Rand Europe, Cambridge, UK; Nicola Allen, PhD, Precision for Value, London, UK; Zoe Garrett, MPhil, MRes, National Institute for Health and Care Excellence (NICE) and EUnetHTA. Manchester, UK

THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM **BOTH SIDES OF THE ATLANTIC**

As the rate of medical innovation accelerates, competing demands from various stakeholders put unprecedented pressure on health systems to deliver high-value medical care. Most health systems claim to link coverage decisions to the value for money afforded by specific treatments, but their approaches to valuation differ. Many countries, such as the United Kingdom, have historically relied on traditional cost-effectiveness analysis using the cost-per-QALY metric to guide coverage decisions. Other countries like France and Germany never adopted the uncertain place of cost-utility analysis in the decision processes, relying instead on disease-specific metrics. The large majority of payers in the pluralistic US health care market deny explicit consideration of cost effectiveness in coverage decisions, and US law forbids its use as part of the Affordable Care Act. Instead, public and private payers in the United States increasingly push financial risk onto health care providers thereby, in a sense, decentralizing the assessment of value. Health economists from the United Kingdom, the United States, and France will provide reflective views on how valuation of medical technologies has changed across time and will discuss the methodological, societal, and political forces that shaped their evolution. The speakers will also consider what the future holds for valuation in health.

Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA Speakers: Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Jérôme Wittwer, PhD, Bordeaux University, Bordeaux, France



IJzerman





Arora





Guthrie





Allen

Garrett



Ryan





Phelps

Reed

Wittwer







A pharmaceutical company that helps you see what others don't

The Mundipharma global network of independent associated pharmaceutical companies successfully builds alliances to develop and market medicines.

We are looking for alliance partners developing therapies in pain, respiratory, oncology and biosimilars or new areas of exploration.

Contact us at: businessdevelopment@mundipharma.co.uk www.mundipharma.com



Mundipharma International Limited proud developers of the BEACON framework

MINT/UNAL - 17017b August 2017



Congress Schedule of Events

SATURDAY, 4 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS Hall 5**

8:00-17:00 SHORT COURSE FULL DAY (Separate Registration Required)

Introduction to Health Economic/Pharmacoeconomic Evaluations Hall 2

Track: Economic Methods

Level: Introductory This course is suitable for those with little or no experience with pharmacoeconomics.

Faculty: Lieven Annemans, PhD, MSc, Ghent University - Brussels University, Ghent, Belgium

8:00-12:00 SHORT COURSE MORNING SESSION (Separate Registration Required)

Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources *Lomond Auditorium (Loch Suite)*

Track: Observational Data Methods

Level: Introductory

Faculty: Linus Jönsson, PhD, MD, MSc, H. Lundbeck A/S, Valby, Denmark; Bradley C. Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

Introduction to Patient-Reported Outcomes Assessment Carron (Loch Suite)

Track: Patient-Reported Outcomes Methods

- Level: Introductory This is an entry level course which assumes only a passing familiarity with patient-reported outcomes.
- Faculty: Kevin Weinfurt, PhD, Duke Clinical Research Institute, Durham, NC, USA

Introduction to Modeling Boisdale (Loch Suite)

Track: Modeling Methods

- Level: Introductory This course is designed for those with some familiarity with modeling techniques.
- Faculty: Uwe Siebert, MD, MPH, MSc, ScD, UMIT University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

Development of Conceptual Models Leven+Morar+Ness (Seminar Suite)

Track: Modeling Methods

Level: Introductory

Faculty: Neil Hawkins, PhD, University of Glasgow, Glasgow, UK; Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; Elisabeth Fenwick, PhD, MSc, ICON Health Economics and Epidemiology, Abingdon, UK; Paul Tappenden, PhD, MSc, University of Sheffield, Sheffield, UK; Beth Woods, MSc, University of York, Heslington, York, UK

Cost-Effectiveness Analysis Alongside Clinical Trials Alsh (Loch Suite)

Track: Economic Methods

- Level: Intermediate Familiarity with economic evaluations will be helpful.
- Faculty: Richard J. Willke, PhD, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA; Lotte Steuten, PhD, Hutchinson Institute for Cancer Outcomes Research (HICOR) and University of Washington, Seattle, WA, USA

Elements of Pharmaceutical / Biotech Pricing Hall 1

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information

- Level: Introductory This course is designed for those with limited experience in the area of pharmaceutical pricing and will cover topics within a global context.
- Faculty: Jack M. Mycka, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; Renato Dellamano, PhD, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy

Conjoint Analysis – Theory & Methods Dochart (Loch Suite)

Track: Patient Preference Methods

- Level: Intermediate This course is designed for clinicians, policymakers, researchers, and patient advocates/researchers with some familiarity with conjoint analysis or other stated-preference methods.
- Faculty: **A. Brett Hauber, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **John F. P. Bridges, PhD**, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

10:00-10:15 **COFFEE BREAK**

Coffee Break Sponsored by Sirius Market Access



12:00-13:00 LUNCH (Attendees on their own)

13:00-17:00 SHORT COURSE AFTERNOON SESSION (Separate Registration Required)

Introduction to Health Technology Assessment Lomond Auditorium (Loch Suite)

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information

- Level: **Introductory** *This course is suitable for those with little or no experience with HTA.*
- Faculty: Uwe Siebert, MD, MPH, MSc, ScD, UMIT University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

Meta-Analysis & Systematic Literature Review Alsh (Loch Suite)

- Track: Outcomes Research Methods
- Level: Intermediate
- Prereq.: Previous attendance at the ISPOR short course, "Statistical Methods for Pharmacoeconomics & Outcomes Research," or equivalent knowledge, is recommended.
- Faculty: Olivia Wu, PhD, University of Glasgow, Glasgow, UK; Neil Hawkins, PhD, University of Glasgow, Glasgow, UK

Statistical Methods for Pharmacoeconomics & Outcomes Research Boisdale (Loch Suite)

- Track: Economic Methods
- Level: Introductory This course is intended for participants with little (or rusty!) statistical training.
- Faculty: James Lewsey, PhD, University of Glasgow, Glasgow, UK; Gerd K. Rosenkranz, PhD, Medical University of Vienna, Vienna, Austria

Use of Propensity Scores in Observational Studies of Treatment Effects Leven+Morar+Ness (Seminar Suite) Track: Observational Data Methods

- Level: Intermediate This course is designed for those with little experience with this methodology but some knowledge of observational databases.
- Prereq.: Previous attendance at the ISPOR short course, "Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources," or equivalent knowledge, is recommended.

Faculty: John D Seeger, PharmD, DrPH, Optum, Waltham, MA, USA; Jeremy A. Rassen, ScD, Aetion, Inc., New York, NY, USA

Collecting Health-State Utility Estimates for Economic Models in Clinical Studies *Carron (Loch Suite)*

Track: Patient Preference Methods

- Level: Intermediate This course is for those with some experience with quality of life measures in health economic evaluation.
- Faculty: Sorrel Wolowacz, PhD, RTI Health Solutions, Manchester, UK; Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd., Oxford, UK; Lynda Doward, MRes, RTI Health Solutions, Manchester, UK
- Pharmacoeconomic Modeling Applications **Dochart (Loch Suite)**

Track: Modeling Methods

Level: Intermediate

- Prereq.: Previous attendance at, or familiarity with the topics discussed in the ISPOR short course, "Introduction to Modeling," is required.
- Faculty: Shelby L. Corman, PharmD, MS, BCPS, Pharmerit International, Bethesda, MD, USA; Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

Indicates hands-on exercises requiring the use of your personal computer.



NEW! Introduction to Designing Authentic and Impactful Patient-Centered Outcomes Research *Hall 1*

Track: Patient-Reported Outcomes Methods

Level: Introductory

Faculty: **C. Daniel Mullins, PhD**, University of Maryland, School of Pharmacy, Baltimore, MD, USA; **Marvin Mack**, Center for Mind & Esteem Development, Baltimore, MD, USA; **Emil Chiauzzi, PhD**, PatientsLikeMe, Cambridge, MA, USA

15:00-15:15 **COFFEE BREAK**

17:30-18:30 EDUCATIONAL SYMPOSIUM (Open to all attendees) Lomond Auditorium (Loch Suite)

The Evolving Approach to Drug Value Assessment in Global Markets

Moderator: David Rees, MBA, Health Strategies Group, Yardley, PA, USA

Speaker: Sanjay Shah, MBA, Visionary Ventures, LLC., Morganville, NJ, USA, **Michael Schlander, MD, PhD, MBA**, InnoVal-HC, Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany, **Andreas Wildi, MD, Mlaw**, Walder Wyss Ltd., Zurich, Switzerland, **Jennifer Cain, MBA, MPH**, Roche, Basel, Switzerland, **Aris Angelis, MSc**, London School of Economics and Political Science, London, UK

(Sponsored by Health Strategies Group)



< advertisement >

< advertisement >



SUNDAY, 5 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS Hall 5**

8:00-18:00 EXHIBITOR SET UP Hall 4

12:00-18:00 SPEAKER READY ROOM HOURS Fyne (Loch Suite)

8:00-17:00 SHORT COURSE FULL DAY (Separate Registration Required)

Bayesian Analysis – Overview and Applications Dochart (Loch Suite)

Track: Modeling Methods

- Level: Intermediate This course is designed for those with a limited understanding of Bayesian statistical concepts or for those who want a refresher and more practical experience.
- Faculty: Christopher S. Hollenbeak, PhD, Penn State College of Medicine, Hershey, PA, USA; Keith R Abrams, PhD, University of Leicester, Leicester, UK

8:00-12:00 SHORT COURSE MORNING SESSION (Separate Registration Required)

NEW! US Payers – An Introduction to Their Structures, Evidence Needs, and Decision-Making Process Hall 2

- Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
- Level: Introductory This course is designed for those having very minimal experience in understanding differences in perspectives and evidence needs for various access decision makers in the US Health Care system.
- Faculty: **Priti Jhingran, PhD**, Allergan, Jersey City, NJ, USA; **Helen Sherman, PharmD, RPh**, Solid Benefit Guidance, Portland, OR, USA

Using DICE Simulation for Health Economic Analyses Carron (Loch Suite)

- Track: Modeling Methods
- Level: Introductory This course is designed for those with some familiarity with modeling.
- Faculty: J. Jaime Caro, MDCM, FRCPC, FACP, Evidera, Waltham, MA, USA and McGill University, Montreal, QC, Canada; Jorgen Moller, MSc, Mech Eng, Evidera, Hammersmith, UK

Use of Instrumental Variables in Observational Studies of Treatment Effects Gala (Armadillo)

- Track: Observational Data Methods
- Level: Intermediate This course is suitable for those with some knowledge of econometrics.
- Prereq.: Previous attendance at the ISPOR short course, "Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources," or equivalent knowledge, is recommended.
- Faculty: Benjamin M. Craig, PhD, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA; Bradley C. Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA; Antoine C. El Khoury, PhD, MS, Janssen GCC, Dubai, United Arab Emirates

Transferability and Relevance of Cost-Effectiveness Data Between Countries Alsh (Loch Suite)

- Track: Economic Methods
- Level: **Advanced** This course is for those with advanced understanding of economic evaluations of health care programs and experience in the critical assessment of cost-effectiveness studies.
- Faculty: **Manuela A. Joore, PhD**, Care and Public Health Research Institute (CAPHRI) and Maastricht University, Maastricht, The Netherlands; **Silvia Evers, PhD, LLM**, Maastricht University, Maastricht, The Netherlands

NEW! Mapping to Estimate Utility Values from Non-Preference Based Outcome Measures Boisdale (Loch Suite)

Track: Patient Preference Methods

Level: Intermediate

Faculty: Allan Wailoo, MA, MSc, PhD, University of Sheffield, Sheffield, UK; Mónica Hernández, MSc, PhD, University of Sheffield, Sheffield, UK; Andrea Manca, MSc, PhD, University of York, Heslington, York, UK



Indicates hands-on exercises requiring the use of your personal computer.

Pudget Impact Analysis I: A 6 Step Appro ach Lomand Auditorium (Lach Suite)

Track:		omic Methods	
Level:	evel: Intermediate This course is designed for those with some experience with pharmacoeconomic analysis.		
Faculty:			
Risk-Sł	naring	/ Performance-Based Arrangements for Drugs and Other Medical Products Forth (Armadillo)	
Track:	Use o	of Pharmacoeconomic / Economic / Outcomes Research Information	
Level:		mediate This course is designed for those with some experience with pharmacoeconomic analysis.	
·	 q.: Helpful for those taking this course to have completed the ISPOR short course "Elements of Pharmaceutical/Biotech Pricing" or to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems. ty: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Office of Health Economics, 		
, acting ,		on, UK; Josh J. Carlson, MPH, PhD, University of Washington, Seattle, WA, USA	
Track:	Mod	ing Survival Modeling with Application to Health Technology Assessment Hall 1 eling Methods	
Level: Faculty:	Andr	mediate ew Briggs, DPhil, University of Glasgow, Glasgow, UK; Christopher Parker, MSc, Celgene Ltd., Uxbridge, UK; Andrew es, MSc, University of Glasgow, Glasgow, UK; Gemma Kay, MSc, ICON Health Economics & Epidemiology, Abingdon, UK	
10:00-1	0:15	COFFEE BREAK DLIMD	
		Coffee Break Sponsored by PHMR PHMR	
12:00-1	3:00	LUNCH (Attendees on their own)	
13:00-1	7:00	SHORT COURSE AFTERNOON SESSION (Separate Registration Required)	
Budge Track:		act Analysis II: Applications & Design Issues Lomond Auditorium (Loch Suite)	
Level:		mediate This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to analyses in Excel.	
Prereq.:		ipation in the ISPOR short course "Introduction to Budget Impact Analysis: A 6-Step Approach," or equivalent knowledge, ommended. Knowledge of Excel is highly recommended.	
Faculty:		hanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park, NC, USA; Anita J. Brogan, PhD, RTI Health ions, Research Triangle Park, NC, USA; Thor-Henrik Brodtkorb, PhD, RTI Health Solutions, Ljungskile, Sweden	
		lethods for Addressing Selection Bias in Real-World Effectiveness and Cost-Effectiveness	
Track:		rvational Data Methods	
Level:	Inter	mediate	
Faculty:		ard Grieve, PhD, London School of Hygiene and Tropical Medicine, London, UK; Noemi Kreif, PhD, London School of ane and Tropical Medicine, London, UK	
Introdu	uction	to the Economic Analysis of Diagnostics Gala (Armadillo)	
Track:		of Pharmacoeconomic / Economic / Outcomes Research Information	
Level:		mediate	
Faculty:		E. Schneider, PhD , Avalon Health Economics, Morristown, NJ, USA; Andrew Briggs, DPhil , University of Glasgow, ow, UK	
		eta-Analysis in Relative Effectiveness Research Carron (Loch Suite)	
Track:		omes Research Methods	
Level:		mediate This course requires at least a basic knowledge of meta-analysis and statistics.	
Faculty:		en P. Jansen, PhD, MSc , Chief Scientist, Precision XTract, Oakland, CA, USA; Steve Kanters, MSc , Precision XTract, buver, BC, Canada	



Indicates hands-on exercises requiring the use of your personal computer.

Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements Hall 1

Use of Pharmacoeconomic / Economic / Outcomes Research Information Track:

Level: Intermediate

Faculty: Zoltán Kaló, PhD, Eötvös Loránd University, Budapest, Hungary; Rok Hren, PhD, MSc IHP (HE), University of Ljubljana, Liubliana, Slovenia; Katarzyna Kolasa, PhD, GHEOR4MEDICALDEVICES and Medical University of Warsaw, Warsaw, Poland

Adjusting for Time-Dependent Confounding and Treatment Switching Bias in Observational Studies and Clinical Trials: Purpose, Methods, Good Practices and Acceptance in Health Technology Assessment Forth (Armadillo)

Observational Data Methods Track:

Intermediate l evel:

Uwe Siebert, MD, MPH, MSc, ScD, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Faculty: Austria; Nicholas Latimer, MSc, PhD, University of Sheffield, Sheffield, UK; Felicitas Kühne, MSc, UMIT, Hall i.T., Austria

Reimbursement Systems for Pharmaceuticals in Europe Hall 2

- Use of Pharmacoeconomic / Economic / Outcomes Research Information Track:
- Level: Intermediate This course is designed for individuals with intermediate experience within a single health care system wishing to broaden their appreciation of other reimbursement systems.
- Faculty: Mondher Toumi, MD, PhD, MSc, Aix-Marseille University, Marseille, France

Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications Alsh (Loch Suite)

Use of Pharmacoeconomic / Economic / Outcomes Research Information Track:

- Introductory The course is designed for those unfamiliar with MCDA, but who have a basic understanding of other evaluation Level: methodologies.
- Faculty: Maarten J. IJzerman, PhD, University of Twente, Enschede, The Netherlands; Kevin Marsh, PhD, Evidera Ltd, London, UK; Nancy Devlin, PhD, Office of Health Economics, London, UK

COFFEE BREAK 15:00-15:15

EDUCATIONAL SYMPOSIUM (Open to all attendees) Lomond Auditorium (Loch Suite) 17:30-18:30

Evaluating Survival Benefits in Technology Appraisals of Innovative Oncology Drugs: Challenges and Practical Solutions

Moderator: Jipan Xie, MD, PhD, Analysis Group, Inc., Los Angeles, CA, USA Speakers: Nicholas Latimer, PhD, ScHARR - University of Sheffield, Sheffield, UK; Zheng-Yi Zhou, PhD, Analysis Group, Inc., London, UK ANALYSIS GROUP

(Sponsored by Analysis Group)

EDUCATIONAL SYMPOSIUM (Open to all attendees) Lomond Auditorium (Loch Suite) 18:45-19:45

How to Use the BEACON Framework to Help Guide the Drug Development Process and Achieve Patient Access

Moderator: Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester, UK Speaker: William Dunlop, MSc, Mundipharma International Ltd, Cambridge, UK; Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Ron Goeree, MA, McMaster University and Goeree Consulting Ltd, Hamilton, ON, Canada

(Sponsored by Mundipharma International Ltd)



MONDAY, 6 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS Hall 5**

7:15-8:30 ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP OPEN MEETING Forth (Armadillo)

7:30-8:30 ISPOR PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP OPEN MEETING Hall 1

7:30-8:30 EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)

Real-World Evidence to Support Regulatory Approvals Based on Tumor Biomarkers in Oncology Research

Moderator: Bruce Feinberg, DO, Cardinal Health Specialty Solutions, Dublin, OH, USA Speakers: Bjorn Bolinder, MBA, AstraZeneca, Gaithersburg, MD, USA; Hui Huang, PhD, MBA, Takeda, Cambridge, MA, USA; Samuel Wagner, PhD, RPh, Bristol-Myers Squibb, Washington Crossing, PA, USA (Sponsored by Cardinal Health)



8:00-18:00 SPEAKER READY ROOM HOURS Fyne (Loch Suite)

8:30-19:45 EXHIBIT/POSTER HALL HOURS Hall 4

8:45-13:45 **RESEARCH POSTERS - SESSION I Hall 4**

8:45-10:45 WELCOME & FIRST PLENARY SESSION Clyde Auditorium (Armadillo)

WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR

Nancy S. Berg, BSc, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA

PRESIDENTIAL ADDRESS

Watford, UK

Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

CONGRESS PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRS

Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

FIRST PLENARY SESSION: Where is the Value in Value-Based Health Care?

Moderator: Maarten J. IJzerman, PhD, University of Twente, Enschede, The Netherlands Speakers: Peter Naredi, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; Luke Slawomirski, Organisation for Economic Co-operation and Development (OECD), Paris, France; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and European Society for Medical Oncology (ESMO), Uppsala, Sweden; Jason Arora, MD, MPH, Medtronic,

10:45-11:15 BREAK, EXHIBITS & RESEARCH POSTERS - SESSION I Hall 4

11:15-12:15 BREAKOUT SESSION

IP1: Pragmatic Clinical Trials to Estimate Treatment Effects: Are They Worth the Effort? Hall 3 Moderator: Rita M. Kristy, MS, Astellas Pharma Global Development, Northbrook, IL, USA Panelists: Keith R. Abrams, PhD, CStat, University of Leicester, Leicester, UK; Christoph Gerlinger, PD, Bayer AG, Berlin, Germany; Helene Karcher, PhD, Analytica Laser, Loerrach, Germany

IP2: How to Improve Consistency of Orphan Drug Pricing and Reimbursement in Europe? Application of the 'Orph-Val' Principles in Germany, France, and the United Kingdom *Clyde Auditorium (Armadillo)*

Moderator: Lieven Annemans, PhD, MSc, Ghent University - Brussels University, Ghent, Belgium Panelists: Karina Ehrig, PhD, Federal Joint Committee (G-BA), Berlin, Germany; Francois Meyer, PhD, Haute Autorité de Santé (HAS), Saint-Denis, France; Sheela Upadhyaya, MSc, National Institute for Health and Care Excellence (NICE), London, UK

W1: Where Do We Need Good Research Practice Guidance in Health Technology Assessment? Hall 2

Discussion Leaders: Finn Børlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark; **Mirjana Huić, MD**, **PhD**, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia; **Wim Goettsch, PhD**, The National Healthcare Institute (ZIN), Diemen, The Netherlands; **Sophie Werkö, PhD, MSc**, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden

W2: Patient Powered Registries: Useful for Health Technology Assessment or Not? Hall 1

Discussion Leaders: Gurmit Sandhu, B Pharm (Hons), MBA, MPH, Gurmit Sandhu Consulting GmbH, Basel, Switzerland; Elisabeth M. Oehrlein, BA, University of Maryland School of Pharmacy, Baltimore, MD, USA; Robert N. McBurney, PhD, Accelerated Cure Project for MS, Waltham, MA, USA; Chantal Guilhaume, PharmD, Haute Autorité de Santé, Saint-Denis La Plaine, France

P1: Cost-Effectiveness Studies Lomond Auditorium (Loch Suite) Cost-Effectiveness of Dabigatran With Real World Effectiveness Evidence CE1 11:15-11:30 de Pouvourville G¹, Guilmet C², Cohen AA³, Le Dissez C⁴, Luciani L⁴, Le Lay K⁴, ¹ESSEC Business School, Cergy-Pontoise, France, ²MAPI Group, Nanterre, France, ³Hôpital saint Antoine, Paris, France, ⁴Boehringer Ingelheim France, Paris, France CE2 Cost-Effectiveness Analysis of Midostaurin (Mido) With Standard Chemotherapy (SOC) for Acute Myeloid 11:30-11:45 Leukemia (AML) in the United Kingdom (UK) Tremblay G¹, Dolph M¹, Patel S², Brandt P³, Forsythe A¹, ¹Purple Squirrel Economics, New York, NY, USA, ²Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK, ³Novartis Pharmaceuticals, East Hanover, NJ, USA First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis CE3 From a UK Healthcare Perspective 11:45-12:00 Hu X, Goldman DP, University of Southern California, Los Angeles, CA, USA The Effectiveness and Cost-Effectiveness of Tobacco Control Mass Media Campaigns in Scotland CE4 12:00-12:15 Haghpanahan H¹, Boyd KA¹, Mackay DF¹, Mcintosh E¹, Pell J¹, Haw S², ¹University of Glasgow, Glasgow, UK, ²University of Stirling, Stirling, UK P2: Cancer Studies Forth (Armadillo) Use of New Therapies and Hospital Admission Near the End of Life in Castration Resistant CN1 11:15-11:30 Prostate Cancer (CRPC) in the Castration Resistant Prostate Cancer Registry (CAPRI) in The Netherlands Kuppen M¹, Westgeest H¹, Van den Eertwegh A², Gerritsen W³, Uyl - de Groot C¹, ¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²VU University Medical Centre, Amsterdam, The Netherlands, ³Radboud University Medical Center, Nijmegen, The Netherlands The Greta Study: Generating Real-World Evidence About Bevacizumab Treatment of Metastatic Colorectal CN2 Cancer by Linking Cancer Registries and Healthcare Databases in Italy 11:30-11:45 Franchi M¹, Caputo A², Barni S³, De Ceglie MC⁴, Mazzucco W⁵, Ricci P⁶, Tagliabue G⁷, Tumino R⁸, Corrao G⁹, ¹University of Milano-Bicocca, Milano, Italy, ²Roche S.p.A., Monza, Italy, ³ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, Italy, ⁴Roche S.p.A, Monza, Italy, ⁵University of Palermo, Palermo, Italy, ⁶Health Protection Agency Mantua&Cremona, NHS Italy, Mantova, Italy, ⁷Fondazione IRCCS National Cancer Institute, Milano, Italy, ⁸Provincial Health Authority, ASP Ragusa, Ragusa, Italy, ⁹Università di Milano-Bicocca, Milan, Italy CN3 Assessing the Consistency in Reporting of Adverse Events Across Data Sources for Multiple Myeloma 11:45-12:00 Treatment Kish J¹, Feinberg B², ¹Cardinal Health Specialty Solutions, Dallas, TX, USA, ²Cardinal Health, Dublin, OH, USA Utilization and Treatment Patterns Among Patients With Advanced Non-Small Cell Lung Cancer Receiving CN4 12:00-12:15 Predictive Molecular Biomarker (BMX) Tests Kothari S¹, Arunachalam A², Tsao M³, Lee DH⁴, Kambartel K⁵, Isobe H⁶, Huang M⁷, Escosteguy Barrios CH⁸, Khattak A⁹, de Marinis F¹⁰, Cao X¹¹, Burke T¹², Lopez MA¹³, De Castro J¹⁴, ¹Merck & Co, Kenilworth, NJ, USA, ²Merck & Co., Inc., North Wales, PA, USA, ³University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁴Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), ⁵Bethanien Hospital, Moers, Germany, ⁶KKR Sapporo Medical Center, Sapporo, Japan, ⁷Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, ⁸PUCRS School of Medicine, Porto Alegre, Brazil, ⁹Flona Stanley Hospital, Murdoch, Australia, ¹⁰European Institute of Oncology, Milan, Italy, ¹¹Merck & Co, Inc, Kenilworth, NJ, USA, ¹²Merck & Co., Inc., Lebanon, NJ, USA, ¹³MSD, Madrid, Spain, ¹⁴Hospital Universitario La Paz, MADRID, Spain LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION I Hall 4 12:15-14:15

Lunch Sponsored by Health Economics and Outcomes Research Ltd.



ISPOR DIGEST OF DATABASES SPECIAL INTEREST GROUP OPEN MEETING Hall 1 12:30-13:30

ISPOR STUDENT RESEARCH SHOWCASE Lomond Auditorium (Loch Suite) 12:45-13:45

Moderators: Zeba Khan, MS, RPh, PhD, Celgene Corporation, Summit, NJ, USA; Laura Pizzi, MPH, RPh, PharmD, Rutgers University, Piscataway, NJ, USA

Speakers: Natalie J. Williams, Msc, NIHR Nottingham Hearing Biomedical Research Unit, Nottingham, UK; Junjie Ma, Msc, University of Utah, Salt Lake City, UT, USA; Omer Ben-Aharon, MBA, MHA, Bar-Ilan University, Ramat Gan, Israel; Fanni Soikkeli, University of Eastern Finland, Joensuu, Kuopio and Savonlinna, Finland

12:45-13:45 EDUCATIONAL SYMPOSIUM Clyde Auditorium (Armadillo)

HTA V2.0: The Relevance of Real-World Evidence in Value Frameworks and Its Relation with Regulatory and Health Technology Assessment Convergence

Moderator: Jacco Keja, PhD, IQVIA, London, UK

Speakers: Maureen Rutten-van Mölken, PhD, MSc, Erasmus School of Health Policy & Management (ESHPM), Rotterdam, The Netherlands; **Dana Vigier, MD**, BMS, Rueil-Malmaison, France; **Elizabeth Powers, MBA**, IOVIA, New York, NY, USA

(Sponsored by IQVIA)



12:45-13:45 POSTER AUTHOR DISCUSSION HOUR - SESSION I Hall 4

14:15-15:15 BREAKOUT SESSION

IP3: Unmet (Medical) Need: Should Stakeholders Align on a Definition? Hall 2

Moderator: Claudine Sapede, PharmD, MSc, F. Hoffmann-La Roche Ltd, Basel, Switzerland Panelists: Hans-Georg Eichler, MD, MSc, European Medicines Agency, London, UK; Nicola Bedlington, The Patient Access Partnership PACT, Brussels, Belgium; Jo De Cock, MS, INAMI - Institut National de l'Assurance Maladie-Invalidité, Brussels, Belgium

IP4: Value Added Medicines: Time to Adjust the Health Technology Assessment Decision Frameworks? Clyde Auditorium (Armadillo)

Moderator: Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK

Panelists: Pascal Auquier, MD, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France; Luigi Burgio, MSc, Teva Italia S.r.I., Assago (MI), Italy; Mondher Toumi, MD, PhD, MSc, Aix-Marseille University, Marseille, France

W3: Making Patient Reported Outcomes Measurement Meaningful: Best Practices for Presenting Patient Reported Outcomes Data to Patients, Clinicians, and Decision Makers *Hall 3*

Discussion Leaders: Jakob B. Bjorner, MD, PhD, Optum Patient Insights, Johnston, RI, USA; Michael Brundage, MSc, FRCPC, MD, Queen's University, Kingston, ON, Canada; Claire Snyder, MHS, PhD, Johns Hopkins School of Medicine, Baltimore, MD, USA; Martha Bayliss, MSc, Optum Patient Insights, Johnston, RI, USA

W4: Bridging the Gap: Best Practices in Navigating Diverging Perceptions of Regulators and Payers on Non-Traditional Clinical Trial Endpoints *Forth (Armadillo)*

Discussion Leaders: Mark Chalmers, PhD, CBPartners, London, UK; **Caroline Solon, MSc**, CBPartners, San Francisco, CA, USA; **Andrew Walker, PhD**, Salus Alba Consulting, Glasgow, UK; **Lung-I Cheng, PhD**, Takeda, Zurich, Switzerland

P3: Studies on Health Technology Assessment Agencies Lomond Auditorium (Loch Suite)

- HT1 Playing in the Same Pond The Impact of Brexit on Clinical Trials and Access
- 14:15-14:30 Wang GD, Macaulay R, PAREXEL International, London, UK

HT2	Health Technology Assessment Decisions in Immuno-Oncology Therapies: Results, Rationales, and Trends
14:30-14:45	<u>Campbell CM</u> , Nguyen VB, Clark RS, Meyer KL, Xcenda, LLC, Palm Harbor, FL, USA

HT3 Analysis of Factors Influencing the Level of Actual Benefit in Health Technology Assessment

14:45-15:00 **Bouschon M**¹, Li J², Barthelemy C³, ¹Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, ²Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, ³Assisance Publique des Hôpitaux de Paris (AP-HP), Paris, France

HT4Using Real-World Data (RWD) in Health Technology Assessment (HTA) Practice: A Comparative Study of15:00-15:155 HTA Agencies

Makady A¹, van Veelen A², Jonsson P³, Moseley O⁴, D'Andon A⁵, de Boer A², Hillege JL⁶, Klungel O², Goettsch W⁷, ¹The National Healthcare Institute (ZIN), Diemen, The Netherlands, ²Utrecht University, Utrecht, The Netherlands, ³National Institute for Health and Care Excellence (NICE), Manchester, UK, ⁴Scottish Medicines Consortium, 50 West Nile Street, UK, ⁵French National Authority for Health, Saint Denis La Plaine, France, ⁶University of Groningen, University Medical Center Groningen, The Netherlands, ⁷Utrecht University, UTRECHT, The Netherlands

P4: Research on Methods Hall 1

RM1 14:15-14:30	Network Meta-Analysis of Hazard Ratios Vs. Fractional Polynomials Approach in a Cost-Effectiveness Analysis Considering Advanced Gastric Cancer <u>Cranmer HL</u> , Harvey RC, Tolley Health Economics Ltd., Buxton, UK
RM2	Multivariate Network Meta-Analysis of Survival Function Parameters
14:30-14:45	Cope S ¹ , Chan K ¹ , Jansen JP ² , ¹ Precision Health Economics, Vancouver, BC, Canada, ² Precision Health Economics, Los Angeles, CA, USA
RM3	Methods for Extracting Treatment Patterns for Renal Cell Carcinoma (RCC) From Social Media (SM)
14:45-15:00	Forums Using Natural Language Processing (NLP) and Machine Learning (ML)
	Merinopoulou E ¹ , Ramagopalan S ² , Malcolm B ² , Cox A ¹ , ¹ Evidera, London, UK, ² Bristol-Myers Squibb, Uxbridge, UK
RM4	Non-Proportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis
15:00-15:15	Gsteiger S ¹ , Windisch R ¹ , Bryden P ¹ , Wiksten A ² , ¹ F. Hoffmann-La Roche Ltd, Basel, Switzerland, ² StatFinn & EPID Research, Espoo, Finland

15:00-16:00 CAREER ADVICE ACROSS THE GLOBE - THE ART OF GETTING PUBLISHED Alsh (Loch Suite)

Speakers: Lyn Beamesderfer, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA; **C. Daniel Mullins, PhD**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **Diego Rosselli, MD, MEd, MHP**, Pontificia Universidad Javeriana, Bogotá, Colombia; **Dan Greenberg, PhD**, Ben-Gurion University of the Negev, Beer-Sheva, Israel

15:15-15:45 BREAK & EXHIBITS Hall 4

Coffee Break Sponsored by Ingress Health



15:45-16:45 BREAKOUT SESSION

IP5: European HTA 2020: What is the Road Map to Effective Permanent Cooperation? (Invited Issue Panel) *Hall 2* **Moderator: Tim Wilsdon**, Charles Rivers Associates, London, UK

Panelists: Wim Goettsch, EUnetHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands; Adrian Griffin, Johnson & Johnson, Buckinghamshire, UK; Nicola Bedlington, European Patients Forum (EPF), Brussels, Belgium; Flora Giorgio, Directorate General for Health and Food Safety (DG SANTE), European Commission, Brussels, Belgium

IP6: Are Existing Health Technology Assessment Requirements Inadequate for Establishing Value for Potentially Transformative Gene Therapies? *Hall 3*

Moderator: Kellie Meyer, PharmD, MPH, Xcenda, Palm Harbor, FL, USA Panelists: Ron Akehurst, PhD, BresMed Health Solutions, Sheffield, UK; Clark Paramore, MSPH, bluebird bio, Cambridge, MA, USA; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK

W5: Sustainable Funding and Fair Pricing for Orphan Drugs: What Are the Solutions? Lomond Auditorium (Loch Suite) Discussion Leaders: Martina Garau, MSc, Office of Health Economics, London, UK; Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK; Saskia Knies, PhD, National Health Care Institute (ZiN), Diemen, The Netherlands; Ulf Staginnus, MBA, Shire plc, Zug, Switzerland

W6: Generating Real-World Evidence for Real-World Decisions: Application of Advanced Methods *Clyde Auditorium* (*Armadillo*)

Discussion Leaders: Mark Sculpher, PhD, University of York, York, UK; **Richard Grieve, PhD**, London School of Hygiene and Tropical Medicine, London, UK; **Anirban Basu, PhD**, University of Washington, Seattle, WA, USA; **Stephen Oneill, MEconSc PhD**, National University of Ireland, Galway, Galway, Ireland

P5: Medication Adherence Studies Hall 1

AD1 15:45-16:00	Exploring Factors Explaining Treatment Acceptance in Patients Suffering From a Chronic Disease Wiederkehr S ¹ , de Bock E ² , Chekroun M ³ , Arnould B ⁴ , ¹ Mapi, Patient Centered Sciences, Lyon, France, ² Mapi, Patient-Centered Outcomes, Lyon, France, ³ Carenity, Paris, France, ⁴ Mapi, Patient Centered Outcomes, Lyon, France
AD2 16:00-16:15	The Impact of Pharmacist-Led Medication Therapy Management on Medication Adherence in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Study <u>Erku DA</u> , Belachew SA, Tegegn HG, Ayele AA, University of Gondar, Gondar, Ethiopia
AD3 16:15-16:30	Factors Associated With an Adherence With Antiepileptic Drugs in Children Treated in Pediatric Practices in Germany Kostev K ¹ , Dombrowski S ¹ , Jacob L ² , ¹ QuintilesIMS, Frankfurt am Main, Germany, ² University of Paris 5, Paris, France
AD4 16:30-16:45	Predictive Analysis for Identifying Patient Characteristics Associated With Primary Medication Nonadherence for Lipid Lowering Therapies Hill JW ¹ , <u>Rane PB</u> ² , Hines DM ¹ , Patel J ² , Harrison DJ ² , Wade RL ¹ , ¹ QuintilesIMS, Plymouth Meeting, PA, USA, ² Amgen Inc., Thousand Oaks, CA, USA
P6: Mental Hea MH1 15:45-16:00	alth Studies Forth (Armadillo) Discrete Event Simulation Modelling of Long Term Cost-Effectiveness of Internet-Based Blended Cognitive Behavioural Therapy for Major Depressive Disorder: Extrapolation of the E-Compared Randomised Controlled Trial <u>O'Connell MM</u> ¹ , Kolovos S ² , Bosmans JE ² , Forbes JF ¹ , E-COMPARED Consortium ³ , ¹ University of Limerick, Limerick,
MH2 16:00-16:15	Ireland, ² Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ³ E-COMPARED Consortium, Europe, Ireland Adherence Patterns Among Patients Using Oral Atypical Antipsychotics and Other Medications <u>Shafrin J</u> ¹ , Lakdawalla DN ² , MacEwan JP ¹ , Silverstein AR ¹ , Hatch A ³ , Forma F ⁴ , ¹ Precision Health Economics, Los Angeles, CA, USA, ² University of Southern California, Los Angeles, CA, USA, ³ ODH, Inc., Princeton, NJ, USA, ⁴ Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA
MH3 16:15-16:30 MH4 16:30-16:45	Model Structure of Patient-Level Models for Schizophrenia: A Systematic Literature Review Zhou J ¹ , Millier A ² , Dorey J ² , Aballéa S ² , Toumi M ¹ , ¹ Aix-Marseille University, Marseille, France, ² Creativ-Ceutical, Paris, France Family Caregiving in Dementia and Its Impact on Quality of Life and Economic Burden in Japan – Web-Based Survey Igarashi A ¹ , Fukuda A ¹ , Teng L ¹ , Ma F ² , Dorey J ³ , Onishi Y ⁴ , ¹ University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ² Creativ-Ceutical, Beijing, China, ³ Creativ-Ceutical, Paris, France, ⁴ Creativ-Ceutical K.K., Tokyo, Japan



15:45-19:30 RESEARCH POSTERS - SESSION II Hall 4

17:00-18:00 BREAKOUT SESSION

IP7: 'Mind the Gap!': How Should We Manage the Difference Between Regulatory and Reimbursement Evidence Requirements for Medical Devices? *Clyde Auditorium (Armadillo)*

Moderator: Bjoern Schwander, AHEAD GmbH (Agency for Health Economic Assessment and Dissemination), Lörrach, Germany Panelists: Richard Charter, MSc, Becton Dickinson, Basel, Switzerland; Karen Facey, PhD, University of Edinburgh, Edinburgh, UK; Nneka C. Onwudiwe, PhD, PharmD, MBA, FDA, Silver Spring, MD, USA

IP8: Forecasting Pharmaceutical Expenditure in Europe: Is It Sustainable? Lomond Auditorium (Loch Suite)

Moderator: Jorge Mestre-Ferrandiz, PhD, Independent Economics Consultant, Madrid, Spain Panelists: Tim Davis, MSc, IQVIA, Basel, Switzerland; Claudio Jommi, PhD, SDA Bocconi School of Management, Milano, Italy; Panos Kanavos, PhD, London School of Economics and Political Science, London, UK

W7: Value of Information (VOI) Analysis for Research Decisions: Emerging Good Practice Recommendations From the ISPOR VOI Task Force *Hall 2*

Discussion Leaders: Elisabeth Fenwick, PhD, MSc, ICON plc, Abingdon, UK; Saskia Knies, PhD, National Health Care Institute (ZiN), Diemen, The Netherlands; Hendrik Koffijberg, PhD, University of Twente, Enschede, The Netherlands; Claire Rothery, PhD, University of York, York, UK

W8: Modeling Separate Lines of Treatment Versus Treatment Sequences in Cancer Hall 3 Discussion Leaders: Agnes Benedict, MSc, Evidera, Budapest, Hungary; Matthew Stevenson, PhD, University of Sheffield, Sheffield, UK; Sonja Sorensen, MPH, Evidera, Bethesda, MD, USA

P7: Conceptual Papers Hall 1

CP1	Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How		
17:00-17:15	Macaulay R, Hettle R, PAREXEL International, London, UK		
CP2	Using Outcome Data to Inform Healthcare Professional – Patient Discussion: A Database of Treatment Effects		
17:15-17:30	Gilbert J, National Guideline Centre, London, UK		
CP3	The Future of Precision Medicine: What Does It Mean for NICE?		
17:30-17:45	Rejon-Parrilla JC ¹ , Lovett RE ² , Chalkidou A ³ , Love-Koh J ⁴ , Wood H ⁴ , Ennis K ⁴ , Peel A ⁴ , Taylor M ⁴ , ¹ National Institute for Health and Care Excellence (NICE), Manchester, UK, ² National Institute for Health and Care Excellence (NICE), London, UK, ³ King's Technology Evaluation Centre (KiTEC), King's College London, London, UK, ⁴ York Health Economics Consortium, University of York, York, UK		
CP4	Challenges in Optimising Real World Evidence for Alzheimer's Disease		
17:45-18:00	<u>Reed</u> C ¹ , de Reydet de Vulpillieres F ² , Gallacher J ³ , ¹ Eli Lilly and Company Ltd, Windlesham, UK, ² NOVARTIS PHARMA AG, Basel, Switzerland, ³ Oxford University, Oxford, UK		
P8: Cardiovas	cular Studies <i>Forth (Armadillo)</i>		
CV1	Interim Results of a Multi-Country Survey to Evaluate Productivity Loss and Indirect Costs After		
17:00-17:15	Cardiovascular Events in Europe		
	Gerlier L ¹ , Sidelnikov E ² , Kutikova L ² , Lamotte M ¹ , Amarenco P ³ , Kotseva K ⁴ , Annemans L ⁵ , ¹ QuintilesIMS, Zaventem, Belgium, ² Amgen (Europe) GmbH, Zug, Switzerland, ³ Bichat Hospital-Claude Bernard, Paris, France, ⁴ National Heart & Lung Institute, Imperial College London, London, UK, ⁵ Ghent University - Brussels University, Ghent, Belgium		
CV2	A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease		
17:15-17:30	Kohli-Lynch CN, Boyd K, Briggs A, Delles C, University of Glasgow, Glasgow, UK		
CV3 17:30-17:45	CYP2C19 Guided Antiplatelet Therapy: A Cost-Effectiveness Analysis of 30-Day and One-Year Outcomes Following Percutaneous Coronary Intervention		
	Dong OM ¹ , Borse MS ¹ , Polasek MJ ² , Farley JF ¹ , Stouffer GA ¹ , Lee CR ¹ , ¹ University of North Carolina, Chapel Hill, NC, USA, ² QuintilesIMS, Durham, NC, USA		
CV4 17:45-18:00	Cost Model for a New Acoustic Diagnostic Aid to Rule Out Coronary Artery Disease Winther S ¹ , Böttcher M ² , <u>Wahler S</u> ³ , Bolin K ⁴ , ¹ Aarhus University Hospital, Aarhus N, Denmark, ² Hjertemedicin Hjerteforskningsklinikken, Herning, Denmark, ³ St. Bernward GmbH, Hamburg, Germany, ⁴ University of Gothenburg, Gothenburg, Sweden		

18:00-19:45 EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTERS - SESSION II Hall 4

ISPOR wishes to thank the Lord Provost & Glasgow City Council for their ongoing assistance, and for their generosity in providing a special welcome drink at Monday evening Exhibitor Reception.

Reception Sponsored by Complete HEOR Solutions (CHEORS)



18:15-19:15 BREAKOUT SESSION

F1: Better, Cheaper, Faster: A Report on the Science of Optimization From the ISPOR Optimization Task Force Hall 3

Moderator: Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK

Speakers: Nasuh Buyukkaramikli, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands; **Praveen Thokala, MASc, PhD**, The University of Sheffield, Sheffield, UK; **Jon Tosh, MSc, PhD**, DRG Abacus, Manchester, UK

Presented by the ISPOR Optimization Task Force

F2: Methods and Preliminary Results of the ISPOR Oncology Health Economic Modeling Special Interest Group Hall 2 Moderator: Noemi Muszbek, MSc, Evidera, London, UK

Speakers: Agnes Benedict, MSc, Evidera, Budapest, Hungary; **Sergio Iannazzo, MBA**, SIHS Health Economics Consulting, Torino, Italy; **Nermeen Nabil Ashoush, PhD**, The British University in Egypt, Cairo, Egypt; **Hena Qureshi, BSc, BA**, University of Calgary, Calgary, AB, Canada

Presented by the Oncology Health Economic Modeling – Post-Progression Working Group of the ISPOR Oncology Special Interest Group

F3: Rare Disease Research, Health Technology Assessment and Evidence for Reimbursement Clyde Auditorium (Armadillo)

Moderator: Sandra Nestler-Parr, PhD, MPhil, MSc, Rare Access Ltd., London, UK

Speakers: Ken Redekop, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands; **Christopher M. Blanchette, PhD, MBA**, Precision Health Economics, Charlotte, NC, USA; **Sheela Upadhyaha, BSc**, National Institute for Health and Care Excellence, London, UK; **Janis Clayton, BSc**, PTC Therapeutics Ltd., Dublin, Ireland

Presented by the ISPOR Rare Disease Special Interest Group

F4: Could Multi-Stakeholder Partnership Improve Patient Access to Better Health Care in Latin America? Hall 1

Moderator: Ramiro E. Gilardino, MD, MSc, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Speakers: Diego F Guarin, MD, MPH, MA, Merck-Serono, Billerica, MA, USA; **Diego Rosselli, MD**, Pontificia Universidad Javeriana, Bogota, Colombia; **Federico Augustovski, MD, MSc, PhD**, University of Buenos Aires, Buenos Aires, Argentina; **Nicola Bedlington**, The Patient Access Partnership PACT, Brussels, Belgium

Presented by the Latin America Consortium

F5: Rare Diseases MCDA Criteria Implementation Results in European Countries Lomond Auditorium (Loch Suite)

Moderator: Olha Zaliska, PhD, DSci (Pharm), Danylo Halytsky Lviv National Medical University, Lviv, Ukraine Speakers: John Yfantopoulos, PhD, University of Athens, Athens, Greece; Francesco Saverio Mennini, MSc, University Tor Vergata Roma, Rome, Italy; Tarik Catic, PhD(s), Health Economics and Pharmacoeconomics, Sarajevo, Bosnia; Rok Hren, PhD, MSc IHP(HE), Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia

Presented by the ISPOR CEE Consortium and ISPOR Italy-Rome Chapter

F6: The Establishment of Negotiation Committee, Therapeutic Guidelines and Health Technology Assessment Efforts in CEE Countries *Forth (Armadillo)*

Moderator: Magda Hatzikou, PhD, Novartis Hellas SA, Athens, Greece

Speakers: Zoltan Kalo, PhD, Syreon Research Institute, Budapest, Hungary; **Dragana Atanasijevic, MD, MSc**, Institute of Public Health of Serbia, Belgrade, Serbia; **Joanna Lis, PhD**, Sanofi, Warsaw, Poland; **Mary Geitona, MD**, University of Peloponnese, Korinthos, Greece

Presented by the ISPOR CEE Consortium

18:15-19:15 ISPOR STATED PREFERENCE METHODS SPECIAL INTEREST GROUP OPEN MEETING Boisdale (Loch Suite)

18:30-19:30 POSTER AUTHOR DISCUSSION HOUR - SESSION II Hall 4

19:45-21:00 ISPOR STUDENT AND NEW PROFESSIONALS MIXER Mezzanine

19:45-21:00 ISPOR CENTRAL & EASTERN EUROPE (CEE) CONSORTIUM RECEPTION Gala Foyer (Armadillo)



TUESDAY, 7 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS Hall 5**

7:30-8:30 EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)

Changing the Health Technology Assessment Paradigm for Combination Therapies

Moderator: Mark Ratcliffe, PhD, PHMR Ltd, London, UK

Speakers: Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Claudio Jommi, MSc, CERGAS Bocconi University, Milan, Italy; Hanim Edoo, MSc, Medi-Qualite Omega, Paris, France; J. Jaime Caro, MDCM, FRCPC, FACP, Evidera, Bethesda, MD, USA (Sponsored by Takeda Pharmaceuticals International AG)



7:45-8:45 ISPOR BIOSIMILAR SPECIAL INTEREST GROUP OPEN MEETING Boisdale (Loch Suite)

8:00-18:00 SPEAKER READY ROOM HOURS Fyne (Loch Suite)

8:30-19:15 EXHIBIT/POSTER HALL HOURS Hall 4

8:45-9:45 BREAKOUT SESSION

IP9: Should Rare Oncology Treatments Be Considered True Orphans? Lomond Auditorium (Loch Suite)

Moderator: Annabel Griffiths, PhD, Costello Medical Consulting Ltd, Cambridge, UK

Panelists: Elangovan Gajraj, MSc, National Institute for Health and Care Excellence, London, UK; Pan Pantziarka, PhD, Anti-Cancer Fund, Strombeek-Bever, Belgium; Ivana Cattaneo, MBA, Novartis Farma S.p.A, Origgio (VA), Italy

IP10: Does Valuation of Innovation in Appraisal of New Technologies Provide Appropriate Incentives for Manufacturers and Access for Patients? *Hall 2*

Moderator: Mark Sculpher, PhD, University of York, York, UK

Panelists: Karl Claxton, PhD, University of York, York, UK; Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Jens Grueger, PhD, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland

W9: Patients' Preferences in the European Regulatory Environment: A Critical Review Forth (Armadillo) Discussion Leaders: Axel C. Mühlbacher, PhD, MBA, Hochschule Neubrandenburg, Neubrandenburg, Germany; Kevin Marsh, PhD, Evidera Ltd, London, UK; Janine A. van Til, PhD, University of Twente, Enschede, The Netherlands

W10: EQ-5D: Is NICE Ready for the Next Level? Hall 3

Discussion Leaders: Rosemary Lovett, PhD, National Institute for Health and Care Excellence (NICE), London, UK; **Allan Wailoo**, **MA**, **MSc**, **PhD**, University of Sheffield, Sheffield, UK; **Nancy Devlin**, **PhD**, Office of Health Economics, London, UK

P9: Medical Device & Diagnostics Studies Hall 1

MD1	Do We Know Enough Yet? A Cumulative Cost-Effectiveness Analysis of Mechanical Thrombectomy
8:45-9:00	<u>Teljeur C</u>¹ , Ryan M ² , Glynn R ³ , Harrington P ⁴ , ¹ Health Information and Quality Authority, Dublin, Ireland, ² Health Information and Quality Authority (HIQA), Dublin, Ireland, ³ Health Service Executive, Dublin, Ireland, ⁴ Health Information and Quality Authority, Dublin 7, Ireland
MD2	South West ICERs – The Experience of Nice's Diagnostics Assessment Programme
9:00-9:15	Nixon F, Walker T, Maloney J, Albrow R, National Institute for Health and Care Excellence, Manchester, UK
MD3	Cost-Effectiveness of Diagnosis: From Tests to Long-Term Outcomes and Costs
9:15-9:30	Faria R ¹ , Soares M ² , Spackman E ³ , Ahmed H ⁴ , Brown L ⁵ , Kaplan RS ⁵ , Emberton M ⁶ , Sculpher M ² , ¹ University of York, Heslington, York, UK, ² University of York, York, UK, ³ University of Calgary, Calgary, AB, Canada, ⁴ Imperial College Healthcare NHS Trust, London, UK, ⁵ MRC Clinical Trials Unit at UCL, London, UK, ⁶ University College Hospitals NHS Foundation Trust, London, UK
MD4 9:30-9:45	Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor <u>Langford BE</u> ¹ , Ridley CJ ¹ , Beale RC ² , Marsh W ¹ , Caseby SC ¹ , Richard L ³ , ¹ Costello Medical Consulting Ltd, Cambridge, UK, ² Costello Medical Consulting Ltd, London, UK, ³ InSightec Ltd, Tirat Carmel, Israel
P10: Method	ds in Patient Preference Studies Gala (Armadillo)
PP1	Mimicking Real Life Decision-Making in Health: Allowing Respondents Time-To-Think in a Discrete Choice
8:45-9:00	Experiment
	<u>Veldwijk J</u> ¹ , Viberg Johansson J ² , Donkers B ¹ , de Bekker-Grob E ¹ , ¹ Erasmus University Rotterdam, Rotterdam, The Netherlands, ² Uppsala University, Uppsala, Sweden

Choice of Instrument Impacts Healthcare Decisions: Effect of Source of Utility Derived From the Same Patient PP2 9:00-9:15 **Population on Cost-Effectiveness** Gunsoy NB¹, Cockle SM², Doyle S², Asukai Y¹, ¹GSK, Uxbridge, UK, ²GSK, Brentford, Middlesex, UK PP3 The Comparative Performance of the CHU-9D and ADQOL Amongst Children Aged 5 Years or More With **Eczema: Evidence From the Clothes Randomised Controlled Trial** 9:15-9:30 Sach TH¹, McManus E¹, Thomas K², Montgomery A², Harrison E², Williams H², on behalf of the CLOTHES trial team², ¹University of East Anglia, Norwich, UK, ²University of Nottingham, Nottingham, UK Does Using Factor Analysis to Select Covariates in Mapping Algorithms Improve Predictive Accuracy? **PP4** A Case of Mapping the Core 23-Item Women's Health Questionnaire Onto the EQ-5D-5L and SF-6D 9:30-9:45 Kaambwa B¹, de Lacey S¹, Smith C², Ratcliffe J³, ¹Flinders University, Adelaide, Australia, ²Western Sydney University, Sydney, Australia, ³University of South Australia, Adelaide, Australia **RESEARCH POSTERS - SESSION III Hall 4** 8:45-13:30 COVANCE MARKET ACCESS **BREAK. EXHIBITS & RESEARCH POSTERS - SESSION III Hall 4** 9:45-10:15 Coffee Break Sponsored by Covance COVANCE 10:15-12:00 WELCOME & SECOND PLENARY SESSION Clyde Auditorium (Armadillo)

WELCOME FROM ISPOR PRESIDENT

Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

WELCOME FROM ISPOR CHIEF SCIENCE OFFICER

Richard J. Willke, PhD, International Society for Pharmacoeonomics and Outcomes Research, Lawrenceville, NJ, USA

2017 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH **OUTCOMES RESEARCH**

AWARDEE: Claire Rothery, PhD, University of York, Heslington, York, UK

2017 VALUE IN HEALTH REGIONAL ISSUES (CEEWAA) EXCELLENT ARTICLE AWARD

AWARDEE: Aleš Tichopád, PhD, Kantar Health s.r.o., Prague, Czech Republic

SECOND PLENARY SESSION: Appraising the Appraisers: What is the Future of Health Technology Assessment in Europe?

Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Speakers: Susan Guthrie, PhD, MSci, Rand Europe, Cambridge, UK; Nicola Allen, PhD, Precision for Value, London, UK; Zoe Garrett, MPhil, MRes, National Institute for Health and Care Excellence (NICE) and EUnetHTA, Manchester, UK

12:00-14:00 LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION III Hall 4 Lunch Sponsored by BaseCase Management GmbH

ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING 12:30-13:30 Lomond Auditorium (Loch Suite)

ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP OPEN MEETING Hall 1 12.30-13.30

EDUCATIONAL SYMPOSIUM Clyde Auditorium (Armadillo) 12:30-13:30

Practical Implications of Value-Based Pricing and Emerging Value Frameworks in Health Technology Assessment

Moderator: Jay Jackson, PharmD, MPH, Xcenda, Palm Harbor, FL, USA

Speakers: Andrew Briggs, DPhil, MSc, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Ansgar Hebborn, PhD, F.Hoffmann-La-Roche AG, Basel, Switzerland; Ken O'Day, PhD, MPA, Xcenda, Palm Harbor, FL, USA (Sponsored by Xcenda)



BASECASE

POSTER AUTHOR DISCUSSION HOUR - SESSION III Hall 4 12:30-13:30



12:30-14:00 ISPOR WOMEN IN HEOR/SCIENCE OPEN MEETING Boisdale (Loch Suite)

ISPOR is exploring the foundation of a "Women in HEOR/Science" initiative to help support the growth, development, and contribution of women in health economics and outcomes research (HEOR) and to serve as a catalyst for women's leadership in the field. The objective of this session is to share the vision for the initiative and to gain feedback from members to help guide its development.

Speakers: 2017-2018 ISPOR President, Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA; Olivia Wu, PhD, University of Glasgow, Glasgow, UK

14:00-15:00 BREAKOUT SESSION

IP11: Determining Value in Health Technology Assessment Consistent with Societal Aims: Pursue New Options? Hall 2 Moderator: J. Jaime Caro, MDCM, FRCPC, FACP, McGill University, Montreal, QC, Canada

Panelists: Alistair McGuire, MLitt, PhD, London School of Economics and Political Science, London, UK; **John Brazier, PhD, MSc**, University of Sheffield, Sheffield, UK; **Michael Schlander, MD, PhD, MBA**, Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany

IP12: What Should Patient-Centered Care Mean in the Welfare States of Europe? The United Kingdom and Germany Cannot Both Be Right *Hall 3*

Moderator: F. Reed Johnson, PhD, Duke Clinical Research Institute, Durham, NC, USA Panelists: Axel C. Mühlbacher, PhD, MBA, Hochschule Neubrandenburg, Neubrandenburg, Germany; Nancy Devlin, PhD, Office of Health Economics, London, UK

W11: Determining the Value of Long Term Outcomes Associated With Immuno-Oncology Therapies - Challenges and Approaches for OS Extrapolations *Clyde Auditorium (Armadillo)*

Discussion Leaders: Yiduo Zhang, PhD, AstraZeneca, Gaithersburg, MD, USA; **Pralay Mukhopadhyay, PhD**, Astrazeneca, Gaithersburg, MD, USA; **Andrew Briggs, DPhil, MSc**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; **Nicholas Latimer, MSc, PhD**, University of Sheffield, Sheffield, UK

W12: Getting to the Heart of the Matter: Real-World Evidence as an Indispensable Source for the Ongoing Assessment of Cardiovascular Treatments *Forth (Armadillo)*

Discussion Leaders: Kathleen E. Hughes, MBA, Avalere Health LLC, Washington, DC, USA; **Colin Berry, FRCP, PhD**, University of Glasgow, Glasgow, UK; **Pall Jonsson, PhD**, National Institute for Health and Care Excellence (NICE), Manchester, UK; **Martin Zagari, MD**, Amgen Inc, Thousand Oaks, CA, USA

P11: Cost Studies Hall 1

CS1 14:00-14:15	Observed Versus Estimated Acquisition Costs Associated With Medicines Recommended by the All Wales Medicines Strategy Group <u>Keeping S</u> , Deslandes PN, Haines K, Routledge PA, All Wales Therapeutics and Toxicology Centre, Llandough, UK
CS2 14:15-14:30	Costs of Chemotherapy-induced Adverse Events in Head and Neck Cancer in France Lafuma A ¹ , Cotte F ² , Le Tourneau C ³ , Emery C ⁴ , Gaudin A ² , Torreton E ¹ , Gourmelen J ⁵ , Ouared C ² , Bonastre J ⁶ , ¹ Cemka- Eval, Bourg La Reine, France, ² Bristol-Myers Squibb, Rueil-Malmaison, France, ³ Institut Curie, Paris, France, ⁴ Cemka, Bourg La Reine, France, ⁵ UMS 011 - Inserm - UVSQ, Villejuif, France, ⁶ Gustave Roussy, Villejuif, France
CS3 14:30-14:45	Costs of Illness Progression for Different Multiple Sclerosis Phenotypes: A Population-Based Study in Sweden <u>Gyllensten H</u> , Kavaliunas A, Hillert J, Alexanderson K, Tinghög P, Friberg E, Karolinska Institutet, Stockholm, Sweden
CS4 14:45-15:00	Real Life Cost of Treatment and Follow-up Glioblastoma Multiforme (GBM) Patients Treated at the Antwerp University Hospital (UZA), Belgium <u>Van den Eede N</u> ¹ , De Paepe A ¹ , Specenier P ² , Strens D ³ , ¹ University of Antwerp, Antwerpen, Belgium, ² Antwerp University Hospital, Edegem, Belgium, ³ Realidad bvba, Grimbergen, Belgium
P12: Modeling MO1 14:00-14:15	Methods Lomond Auditorium (Loch Suite) Calibration Approach Impact on Health and Cost-Effectiveness Outcomes in a Decision Analytic Framework Moriña D, Díaz M, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain
MO2 14:15-14:30	How Ireland's Colorectal Screening Programme Could Save More Lives, Save Money and Stay Within Existing Colonoscopy Capacity Limits: Evidence From the MISCAN Microsimulation Model <u>McFerran E¹</u> , O'Mahony JF ² , ¹ QUEEN'S UNIVERSITY BELFAST, BELFAST, UK, ² Trinity College Dublin, Dublin, Ireland
MO3 14:30-14:45	Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology <u>Majer IM</u> ¹ , Castaigne J ² , Palmer S ³ , DeCosta L ⁴ , Campioni M ¹ , ¹ Amgen (Europe) GmbH, Zug, Switzerland, ² Amgen Oncology, Cambridge, UK, ³ University of York, Heslington, York, UK, ⁴ Amgen Ltd., Uxbridge, UK
MO4 14:45-15:00	Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness and Cost-Effectiveness Analyses <u>Keeney E¹</u> , Dawoud D ² , Dias S ¹ , ¹ University of Bristol, Bristol, UK, ² National Guideline Centre, Royal College of Physicians, London, UK

15:00-15:30 BREAK & EXHIBITS Hall 4

15:30-16:30 BREAKOUT SESSION

IP13: MCDA Valuation and ICERs – Can They Align for Decision-Making Purposes? (Invited Issue Panel) Clyde Auditorium (Armadillo)

Moderator: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA

Panelists: Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; **Maarten Ijzerman, PhD, MSc**, University of Twente, Enschede, The Netherlands; **Nancy Devlin, PhD**, Office of Health Economics, London, UK

IP14: Patient-Centered Decision Making: How Do You Generate Relevant Patient-Reported Outcomes Evidence for Chronic Disease Management and Market-Access Decision Making? *Hall 3*

Moderator: Finn Børlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark

Panelists: Katharine Barnard, PhD CPsychol AFBPsS, Bournemouth University, Poole, UK; Simon O'Neill, REG.N., Diabetes UK, London, UK; Francois Meyer, PhD, Haute Autorité de Santé (HAS), Saint-Denis, France

W13: Why is Your Outcome Different from Mine? Discussing the Potential Impact of Design Choices in the Development of Discrete Event Simulation Models *Lomond Auditorium (Loch Suite)*

Discussion Leaders: Elisabeth Fenwick, PhD, MSc, ICON plc, Abingdon, UK; **Hendrik Koffijberg, PhD**, University of Twente, Enschede, The Netherlands; **Beate Jahn, PhD**, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; **Koen Degeling, MSc**, University of Twente, Enschede, The Netherlands

W14: Impact of Patient Involvement in Health Technology Assessments: A Case Study Hall 2

Discussion Leaders: Matthew May, BS, EPF, Brussels, Belgium; **Joan Jordan**, Multiple Sclerosis Society of Ireland, Dublin, Ireland; **Michael Barry, MB, FRCPI, PhD**, National Centre for Pharmacoeconomics (NCPE), Dublin, Ireland; **Orlaith Brennan, MBA**, Irish Pharmaceutical Industry Association, Dublin, Ireland

P13: Methodological Studies in Cancer Hall 1

CN5	Progression-Free Survival As a Surrogate Endpoint for Overall Survival in Patients With Relapsed or
15:30-15:45	Refractory Multiple Myeloma <u>Dimopoulos M</u> ¹ , Sonneveld P ² , Nahi H ³ , Kumar S ⁴ , Hashim M ⁵ , Kulakova M ⁵ , Duran M ⁵ , Heeg B ⁵ , Lam A ⁶ , Dearden L ⁶ , ¹ National and Kapodistrian University of Athens, Athens, Greece, ² Erasmus MC, Rotterdam, The Netherlands, ³ Karolinska Institute, Stockholm, Sweden, ⁴ Mayo Clinic, Rochester, MN, USA, ⁵ Ingress Health, Rotterdam, The Netherlands, ⁶ Janssen Global Services, LLC, Raritan, NJ, USA
CN6	Can Bayesian Methodology Predict Long-Term Effectiveness Rather Than Efficacy? An Application With
15:45-16:00	Overall Survival in Two Oncology Indications <u>Soikkeli F</u> ¹ , Hashim M ¹ , Mueller S ² , Groth A ² , Wilke T ³ , Heeg B ¹ , ¹ Ingress Health, Rotterdam, The Netherlands, ² Ingress- Health HWM GmbH, Wismar, Germany, ³ INGRESS-Health HWM GmbH, Wismar, Germany
CN7	Estimating Long-Term Survival in the Face of Immature Data: A Case Study of Nivolumab in Second Line
16:00-16:15	Renal Cell Carcinoma <u>Klijn SL</u> ¹ , Torkilseng EB ² , Tyas D ³ , Sowdani A ³ , Malcolm B ³ , Mudd A ¹ , Johannesen KM ⁴ , ¹ Pharmerit International, Rotterdam, The Netherlands, ² Bristol-Myers Squibb, Lysaker, Norway, ³ Bristol-Myers Squibb, Uxbridge, UK, ⁴ Bristol-Myers Squibb AB, Stockholm, Sweden
CN8 16:15-16:30	Length of Trial Period and Fit of Standard Survival Extrapolation Distributions for Ipilimumab in Melanoma Ouwens MJ, Dalevi D, Astrazeneca, Molndal, Sweden
P14: Systemic	Disorders/Conditions Studies Forth (Armadillo)
SY1 15:30-15:45	Psoriasis Drugs in Europe - Market Access Decisions in Comparison Based on the Prism Access Database <u>Vollmer L</u> ¹ , de Paz B ² , Droeschel D ¹ , Walzer S ¹ , ¹ MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, ² PRIORITIS Market Access, Paris, France
SY2	WITHDRAWN
SY3 15:45-16:00	How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents As Therapy Areas Become Crowded With Drugs With Similar Mechanisms of Action? <u>Paglia R</u> , Del Carlo A, Schwartz J, Carter EA, Consulting at McCann Health, New York, NY, USA
SY4 16:00-16:15	Do EU5 Countries With Favourable Healthcare Expenditure and Reimbursement Indicators Have Better Patient-Reported Access to Treatments for Rare Diseases? Allen G ¹ , Hall A¹ , Hanman K ² , Le Fevre R ¹ , Griffiths A ¹ , ¹ Costello Medical Consulting Ltd, Cambridge, UK, ² Costello
	Medical Consulting Ltd, London, UK

15:30-19:15 RESEARCH POSTERS - SESSION IV Hall 4



16:45-17:45 BREAKOUT SESSION

IP15: A Modest Proposal: Can We Ease the Burden of Myriad Measures with a Minimum Data Set That Actually Matters to Patients? *Hall 1*

Moderator: Roman Casciano, MS, ANALYTICA LASER, New York, NY, USA

Panelists: Sheela Upadhyaya, MSc, NICE - National Institute for Health and Care Excellence, London, UK; Charles D. Petrie, PhD, Pfizer, Inc., Groton, CT, USA; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and Uppsala University, Uppsala, Sweden

IP16: Managed Entry Schemes for Medical Devices: Great Opportunity or Major Challenge? Hall 3 Moderator: Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK Panelists: Aleksandra Torbica, PhD, Bocconi University, Milano, Italy; Richard Charter, MSc, Becton Dickinson, Allschwil,

Switzerland; Denis Gizzi, BSc, Sheffield Hallam University, Oldham, UK

W15: Time for a Change? Alternative Approaches to Modelling in Cancer Value Assessments *Clyde Auditorium (Armadillo)*

Discussion Leaders: Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence (NICE), London, UK; **Robert Hettle, MMath**, PAREXEL International, London, UK; **Beth Woods, MSc**, University of York, Heslington, York, UK; **Marta Soares, MSc**, University of York, Heslington, York, UK

W16: Understanding the Value and Feasibility of Engaging Patients in the Design of Clinical Trials and Clinical Outcome Assessment Measurement Strategies: Insights from Experiences in Oncology and Gout Lomond Auditorium (Loch Suite) Discussion Leaders: Bryan Bennett, PhD, Adelphi Values Ltd, Bollington, Cheshire, UK; Sophi Tatlock, MA, Adelphi Values Ltd, Bollington, Cheshire, UK; Stephanie Manson, PhD, Novartis, East Hanover, NJ, USA; Katja Rudell, PhD, Queen Mary University of London, London, UK

P15: Health Technology Assessment Studies Hall 2

HT5	"Appraising The Appraisers": Do National Health Technology Assessment Agencies (NICE, GBA/IQWIG)		
16:45-17:00	Follow Their Official Evaluation Criteria?		
	Schaefer R ¹ , Schwarz O ² , Schlander M ³ , ¹ German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany, ² University of Heilbronn, Wiesbaden, Germany, ³ University of Heidelberg, Heidelberg, Germany		
HT6	Assessment of Medicines for Very Rare Conditions: Review of a New Approach Within the Scottish		
17:00-17:15	Medicines Consortium		
	Jones J, Brown A, Lee A, MacDonald A, Healthcare Improvement Scotland, Glasgow, UK		
HT7	What Do the Single Technology Appraisals of the Past Tell Us About Fast-Tracking the Most Cost-Effective		
17:15-17:30	New Technologies in the Future?		
	Boland A ¹ , Houten R ¹ , Carroll C ² , Kaltenthauer E ² , Dickson R ¹ , ¹ University of Liverpool, Liverpool, UK, ² University of Sheffield, Sheffield, UK		
HT8	The Use of Published Real-World Evidence in HTA: An Analysis of the Evidence Base of Company		
17:30-17:45	Submissions in 2016 NICE Appraisals		
	Van Lier H , de Boeck M, Edwards V, Hanekamp E, Hartog TE, Richmond G, van den Broek R, Excerpta Medica, Amsterdam, The Netherlands		
P16: Infectiou	us Disease Studies <i>Forth (Armadillo)</i>		
IN1 16:45-17:00	Estimating the Public Economic Impact of Different Hepatitis C Healthcare Policies in the Netherlands <u>Connolly M</u> ¹ , Kotsopoulos N ² , ¹ University of Groningen, Groningen, The Netherlands, ² Global Market Access Solutions, Saint-Prex, Switzerland		
IN2	Cost-Effectiveness and Modeling Approaches of Direct-Acting Antiviral Agents in Chronic Hepatitis C		
17:00-17:15	Infection: A Systematic Literature Review		
	<u>Szilberhorn L</u> 1, Ágh T2, Fasseeh AN1, Kaló Z1, 1Eötvös Loránd University (ELTE), Budapest, Hungary, 2Syreon Research		
	Institute, Budapest, Hungary		
IN3	Differences in Vaccine Pricing Between High-Income and Low-Income Markets		
17:15-17:30	Fadeyi I, McLean T, Tavella F, <u>Heron L</u> , Adelphi Values Ltd, Bollington, UK		
IN4	Cost-Effectiveness of Additional Vaccination of Boys Against HPV in Germany		
17:30-17:45	Damm O ¹ , Horn J ² , Ultsch B ³ , Scholz S ¹ , Mikolajczyk R ² , Wiese-Posselt M ³ , Harder T ³ , Wichmann O ³ , Greiner W ¹ , ¹ School of Public Health, Bielefeld University, Bielefeld, Germany, ² Helmholtz Centre for Infection Research, Brunswick, Germany, ³ Immunisation Unit, Robert Koch Institute, Berlin, Germany		
17:45-19:15	EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTERS - SESSION IV Hall 4		

Reception Sponsored by Pharmerit International

phar**merit**

18:00-19:00 BREAKOUT SESSION

F7: Health State Utility Identification and Use in Cost-Effectiveness in Decision Modelling *Clyde Auditorium (Armadillo)* Moderator: John Brazier, PhD, MSc, University of Sheffield, Sheffield, UK

Speakers: Helene Chevrou-Severac, PhD, Celgene International, Boudry, Switzerland; Roberta Ara, MSc, The University of Sheffield, Sheffield, UK; Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd., Oxford, UK

Presented by ISPOR Health State Utility Good Practices Task Force

F8: Innovation and Market Access in Asia-Pacific: What Evidence and Processes Are Appropriate for Reimbursement? China, Japan, South Korea, Taiwan and Australia Compared *Hall 3*

Moderator: Mendel Grobler, B.Pharm, MBA, Amgen Inc., North Ryde, NSW, Australia

Speakers: Shanlian Hu, MS, MD, Shanghai Health Development Research Center, Shanghai, China; **Bruce Crawford, MPH, MA**, InVentiv Health Japan G.K., Tokyo, Japan; **Sukyeong Kim, PhD, RPh, MPH**, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South); **Chee-Jen Chang, PhD, MS**, Taiwan Society for Pharmacoeconomics and Outcome Research, Clinical Informatics and Medical Statistics Research Center, and Professor, Chang Gung University, Tao Yuan, Taiwan

Presented by ISPOR Asia Consortium Industry Committee

F9: Late Stage Oncology MCDA Criteria Implementation Results in European Countries Hall 1

Moderator: Vladimir Zah, PhD, ZRx Outcomes Research Inc., Belgrade, Serbia

Speakers: Oresta Piniazhko, PhD, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine; **Niki Popper**, University of Technology Vienna, Vienna, Austria; **Aleksandra Zawodnik, MSc Pharm**, Medical University of Warsaw, Warsaw, Poland; **Bertalan Nemeth, MSc**, Syreon Research Institute, Budapest, Hungary

Presented by the ISPOR CEE Consortium and ISPOR Austria Chapter

F10: The Burden of COPD in Central & Eastern Europe Forth (Armadillo)

Moderator: Maria Kamusheva, PhD, Medical University of Sofia, Sofia, Bulgaria

Speakers: Josip Culig, MD, PhD, Andrija Stampar Institute of Public Health, Zagreb, Croatia; **Konstantin Tachkov**, PhD(c), Medical University of Sofia, Sofia, Bulgaria; **Tamas Agh, MD, MSC, PhD**, Syreon Research Institute, Hungary, Hungary; **Mary Geitona, MD**, University of Peloponnese, Korinthos, Greece

Presented by the ISPOR CEE Consortium

F11: The New Paradigm of Cancer Treatments: A Challenge for the Health Systems? *Lomond Auditorium (Loch Suite)* Moderator: Carme Pinyol, MD, PhD, MSc, Pierre Fabre, Barcelona, Spain

Speakers: César Hernández, PhD, Spanish Agency of Medicines and Health Products, Barcelona, Spain; **Jorge Mestre-Ferrandiz**, **PhD**, OHE Collaborator, Madrid, Spain

Presented by ISPOR Spain Chapter

F12: Implementing Adaptive Pathways in Europe: A Central and Eastern Europe (CEE) Focus Hall 2

Speakers: André Broekmans, MD, PhD, Lygature and ADAPT SMART, Utrecht, The Netherlands; **Zoltán Kaló, PhD**, Eötvös Loránd University (ELTE) and Syreon Research Institute, Budapest, Hungary; **Tomas Tesar, PharmD, PhD, MBA, MPH, Msc**, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak Republic; **Dominik Tomek, PharmD, MPH, PhD, MSc**, European Patients Forum and Association for Patients' Right Protection in Slovakia, Bratislava, Slovakia

18:15-19:15 POSTER AUTHOR DISCUSSION HOUR - SESSION IV Hall 4

19:30-23:30 **ISPOR SOCIAL EVENT** (Separate Registration Required) **Merchant Square**

Join us for whisky tasting, dinner, and traditional dancing and music.

The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.

Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-to-learn traditional dancing.

Separate registration required. The price is €90 and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment. Registration subject to availability, see the ISPOR Registration desk for details.

- If you have pre-registered for the Social Event, your ticket will print out with your name badge. You will need this ticket for entry to the bus/event.
- Buses will depart from the SEC between 19:30 and 20:00 for the 15-minute journey to Merchant Square.
- Return buses will start at 21:00, last bus at 23:15.





WEDNESDAY, 8 NOVEMBER

7:30-8:30 EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)

Universal Value, The Way Forward?

Speakers: Michael Blackney, PhD, Covance Market Access, London, UK; Ruth Zeidman, PhD, Covance Market Access, London, UK; Emanuela Castelnuovo, MSc, Covance Market Access, London, UK; Michael F. Drummond, MCom, DPhil, University of York, Heslington, York, UK; Don Redding, BA, National Voices, London, UK (Sponsored by Covance)

COVANCE

8:00-16:00 **REGISTRATION HELP DESK HOURS Hall 5**

8:00-15:30 SPEAKER READY ROOM HOURS Fyne (Loch Suite)

8:30-14:15 EXHIBIT/POSTER HALL HOURS Hall 4

8:45-14:00 **RESEARCH POSTERS - SESSION V Hall 4**

8:45-9:45 **BREAKOUT SESSION**

IP17: Deriving Utility Measures from Disease-Specific Quality of Life Instruments: Does Mapping to Generic Utility Instruments Adequately Capture the Patient Perspective in Economic Evaluation? *Hall 3*

Moderator: Samuel Aballéa, PhD, Creativ-Ceutical, Paris, France

Panelists: Linda Abetz-Webb, MA, Patient-Centred Outcomes Assessments, Bollington, UK; Keith Tolley, Tolley Health Economics Ltd., Buxton, UK; Clément François, PhD, Lundbeck, Deerfield, IL, USA

IP18: How Will Health Care Systems Handle Future Oncology Combination Product Launches? Hall 2

Moderator: Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and Uppsala University (Department EBC), Uppsala, Sweden Panelists: Martina Weiss-Radtke, MBA, Helsana Versicherungen AG, Zurich, Switzerland; Jens Grueger, PhD, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland; Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester, UK

IP19: Can the Patient Voice Be Better Incorporated Into the NICE Process? Lomond Auditorium (Loch Suite) Moderator: Eric Low, NA, East Lothian, UK

Panelists: Jennifer Lee, MBA, Janssen UK, High Wycombe, UK; Heidi Livingstone, BA, NICE, London, UK; Richard Jackson, PGCE, NPQH, Patient Expert, Cheshire, UK

W17: Comparing, Contrasting, and Validating Health Economic Decision Models: Experiences From the Latest Mt. Hood Challenge in Diabetes and Lessons for Other Disease Areas *Hall 1*

Discussion Leaders: Alan Brennan, PhD, University of Sheffield, Sheffield, UK; **Mark Lamotte, MD**, IQVIA, Zaventem, Belgium; **Talitha Feenstra, PhD**, RIVM /UMCG, Bilthoven, The Netherlands; **Michael Willis, PhD**, The Swedish Institute for Health Economics, Lund, Sweden

W18: From One to Many: When Groups – Not Czars – Make Decisions Forth (Armadillo)

Discussion Leaders: Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; **Guruprasad Madhavan, PhD**, National Academies of Science, Engineering, and Medicine, Washington, DC, USA

9:45-10:00 BREAK, EXHIBITS & RESEARCH POSTERS - SESSION V Hall 4

10:00-11:00 BREAKOUT SESSION

IP20: Should ICER Be NICE (or Not)? How ICER's New Cost-Effectiveness Framework Compares with NICE's Guidelines Hall 3 Moderator: Matthew Sussman, MA, Boston Health Economics, Waltham, MA, USA

Panelists: Dan Ollendorf, PhD, Institute for Clinical and Economic Review, Boston, MA, USA; Pall Jonsson, PhD, National Institute for Health and Care Excellence (NICE), Manchester, UK

IP21: Adaptive Pathways for Transformative Medicinal Products: A New Paradigm with the Enhanced Application of Real-World Evidence? *Hall 2*

Moderator: David Schwicker, MA, ORPHA Strategy Consulting, Basel, Switzerland Panelists: Nicola Bedlington, The Patient Access Partnership PACT, Brussels, Belgium; Ad Schuurman, MA, National Health Care Institute (ZIN), AH, The Netherlands; Rob Thwaites, MA, MCom, Takeda, London, UK

IP22: How Can We Assess the Value of New Antibiotics? Lomond Auditorium (Loch Suite)

Moderator: Chris Henshall, PhD, Office of Health Economics, London, UK Panelists: Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK; Douglas Lundin, PhD, TLV, Stockholm, Sweden; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK

W19: Generating Evidence to Support Off-Label Higher Value Cancer Treatment Regimens Hall 1

Discussion Leaders: Mark Sculpher, PhD, University of York, York, UK; **Mark J. Ratain, MD, FASCO**, The University of Chicago, Chicago, IL, USA; **Peter Clark, MA, MD, FRCP**, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK; **Virginia Acha, PhD**, MSD Ltd., Hertfordshire, UK

W20: Disconnected or Limited Evidence in Network Meta-Analysis: What Can Be Done? Forth (Armadillo) Discussion Leaders: Howard Thom, MSc, PhD, University of Bristol, Bristol, UK; Joy Leahy, BSc, Trinity College Dublin, Dublin, Ireland; Jeroen P. Jansen, PhD, MSc, Precision Health Economics, Vancouver, BC, Canada

11:15-12:45 WELCOME & THIRD PLENARY SESSION Clyde Auditorium (Armadillo)

WELCOME FROM ISPOR PRESIDENT, PRESENTATION OF ISPOR DISTINGUISHED SERVICE AWARDS, AND ANNOUNCEMENT OF ISPOR 21ST ANNUAL EUROPEAN CONGRESS

Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

AWARDEES:

Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

THIRD PLENARY SESSION: Evolution of Value: Perspectives From Both Sides of the Atlantic

Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA Speakers: Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Jérôme Wittwer, PhD, Bordeaux University, Bordeaux, France

12:45-14:15 LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION V Hall 4

13:00-14:00 EDUCATIONAL SYMPOSIUM Lomond Auditorium (Loch Suite)

Does Accelerated Approval Deliver Accelerated Access? Experiences, Challenges, and Priorities

Moderator: Victoria Tzouma, MSc, London School of Economics and Political Science, London, UK Speakers: Panos Kanavos, PhD, London School of Economics and Political Science, London, UK; Chris Hoyle, PhD, AstraZeneca, Cambridge, UK

(Sponsored by AstraZeneca)

AstraZeneca

13:00-14:00 POSTER AUTHOR DISCUSSION HOUR - SESSION V Hall 4

14:15-15:15 BREAKOUT SESSION

IP23: How Do You Incorporate the Patient Perspective into Health Technology Assessments? Defining Best Practices for Rigorous Scientific Evidence and Impactful Submissions and Reviews *Hall 3*

Moderator: Judith Leah Rubinstein, MIA, Context Matters Inc., New York, NY, USA Panelists: Paola Kruger, MA, Accademia dei Pazienti/EUPATI Italia, Rome, Italy; Ken Bond, MA, CADTH, Ottawa, ON, Canada; Laure Delbecque, PhD, Pharmerit International, Rotterdam, The Netherlands

IP24: Trusting the Results of Model-Based Economic Analyses: Is There a Pragmatic Validation Solution? Hall 2 Moderator: J. Jaime Caro, MDCM, FRCPC, FACP, McGill University, Montreal, QC, Canada Panelists: Matt Stevenson, PhD, University of Sheffield, Sheffield, UK; Jorgen Moller, MSc, Mech Eng, Evidera, Hammersmith, UK; Salah Ghabri, PhD, Haute Autorité de Santé, Saint-Denis La Plaine, France

IP25: Innovative Clinical Trial Designs: Welcomed by Regulators But What About the Payers? Forth (Armadillo) Moderator: Richard Macaulay, PhD, PAREXEL International, London, UK Panelists: Leanne Larson, MHA, PAREXEL International, Waltham, MA, USA; Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Detlev Parow, MD, MBA, D A K - Gesundheit, Hamburg, Germany

W21: Comparing Treatments by Combining Data from Various Randomized and Observational Studies: Introduction to Concept, Methods, and Application Hall 1

Discussion Leaders: Viktor Chirikov, PhD, Pharmerit International, Bethesda, MD, USA; **Susanne Schmitz, PhD**, Luxembourg Institute of Health, Strassen, Luxembourg; **Farhan Mughal, MRPharmS, MSc**, Celgene Ltd, Uxbridge, UK

W22: Negotiating Price and Data in an Era of Conditional Approval: "Stick" or "Twist"? Lomond Auditorium (Loch Suite) Discussion Leaders: Daniel Gladwell, MSc, BresMed Health Solutions LTD, Sheffield, UK; Warren Cowell, MSc, Janssen Inc., High Wycombe, UK; Mark Strong, PhD, University of Sheffield, Sheffield, UK; Ash Bullement, BSc, BresMed Health Solutions, Sheffield, UK



15:15-15:30 BREAK Concourse

15:30-16:30 BREAKOUT SESSION

IP26: mHealth Among Clinicians and Patients in Cancer Care: How to Address the Digital Divide? Forth (Armadillo) Moderator: Rosanna Tarricone, PhD, Bocconi University, Milan, Italy

Panelists: Maria Cucciniello, PhD, Bocconi University, Milan, Italy; Roma Maguire, PhD, MSc, University of Surrey, Glasgow, UK; Nicola Scalzo, MSc, European Commission, Brussels, Belgium

IP27: Valuing Children's HRQoL for Health Technology Assessment: What Are the Issues and Challenges? Hall 2

Moderator: Nancy Devlin, PhD, Office of Health Economics, London, UK Panelists: Oliver Rivero-Arias, PhD, MSc, University of Oxford, Oxford, UK; Donna Rowen, PhD, University of Sheffield, Sheffield, UK; Deborah Morrison, MSc, NICE, Manchester, UK

IP28: Patient Preferences in European Drug Regulation – Are We Ready? Hall 1

Moderator: Douwe Postmus, PhD, University Medical Center Groningen, Groningen, The Netherlands Panelists: Francesco Pignatti, MD, European Medicines Agency, London, UK; Pierre Demolis, MD, PhD, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Saint-Denis, France; Tommi Tervonen, PhD, Evidera, London, UK

W23: Improving Performance of Algorithms to Power Unmet Need and Effectiveness in Health Economics and Outcomes Research Using Electronic Health Records and Health Care Claims Data Sources *Lomond Auditorium (Loch Suite)* Discussion Leaders: Hoa Van Le, MD, PhD, PAREXEL International, Durham, NC, USA; Aaron WC Kamauu, MD, MS, MPH, Anolinx LLC, Salt Lake City, UT, USA; Schiffon L Wong, MPH, EMD Serono, Inc., Billerica, MA, USA

W24: Population-Adjusted Treatment Comparisons in Health Technology Assessment: An Overview of Approaches and Perspectives *Hall 3*

Discussion Leaders: David M. Phillippo, MSc, University of Bristol, Bristol, UK; **Ahmed Elsada, MSc**, National Institute for Health and Clinical Excellence, Manchester, UK; **Mark Belger, BSc**, Eli Lilly and Company, Surrey, UK; **Nicky J. Welton, PhD, MSc**, University of Bristol, Bristol, UK



For more than 230 years, we have been serving society with innovative medicines and helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

We continue to transform the future of healthcare by unifying our strengths around the world. We are a diverse organization committed to working with local communities to fully understand their needs and deliver industry-leading solutions with a sense of urgency, dedication and unparalleled efficiency.

Our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world.

©2017 Takeda Pharmaceutical Company Limited. All rights reserved.

Mark your Calendars! UPCOMING ISPOR EVENTS

23RD ANNUAL INTERNATIONAL MEETING May 19-23, 2018 Baltimore, MD, USA

Abstract Submission Deadline: January 17, 2018 Early Registration Deadline: April 10, 2018

8TH ASIA-PACIFIC CONFERENCE 8-11 September 2018

Tokyo, Japan

Abstract Submission Opens: 1 November 2017 Abstract Submission Deadline: 14 March 2018 Early Registration Deadline: 17 July 2018

21ST ANNUAL EUROPEAN CONGRESS 10-14 November 2018 Barcelona, Spain

Abstract Submission Opens: 1 March 2018 Abstract Submission Deadline: 13 June 2018 Early Registration Deadline: 25 September 2018

WING TECH INC.

Independent analytical expertise to help **innovators** discover, validate, and articulate the **value** of medical technologies



Tuesday, November 7 8:45 am – 1:30 pm

Changes in Acute Medication Cost Observed in Cluster Headache Patients Treated with Sphenopalatine Ganglion (SPG) Stimulation: A UK NHS-Specific Analysis Based on Data from the Pathway R1 Registry (Research Posters III, abstract PMD34)

Clinical and Economic Benefit of Upper Airway Stimulation for Obstructive Sleep Apnea in the German Setting

(Research Posters III, abstract PMD51)

wing-tech.com • consulting@wing-tech.com • +1-650-943-3000 Menlo Park, CA • Irvine, CA • Potomac, MD • Karlsruhe, Germany Better Analysis ^{for} Better Decisions

Visit us at the 2017 ISPOR European Congress, booth 113

30 | #ISPORGlasgow

Invitational Group Meetings

The following is a list of the by invitation only ISPOR group meetings during ISPOR Glasgow. ISPOR members worldwide are actively participating in ISPOR working groups to advance global health outcomes research and the use of this research in health care decisions. These ISPOR groups provide an opportunity for members to contribute to translating outcomes research to health care decisions.

Please note: invitees will receive an email reminder and notification of any changes to this ISPOR group meeting schedule

SUNDAY, 5 NOVEMBER

Lunch on your	own for short course delegates	
8:30-15:00	ISPOR HTA Roundtable - Europe	Gallery Bistro (upstairs off the Mezzanine)
11:30-12:30	ISPOR Publications Management Advisory Board and Journal Editors-in-Chief Joint Business Meetin	<i>Katrine (Seminar Suite)</i> Ig
12:00-12:45	ISPOR HTA Roundtable - Europe Luncheon	Gallery Bistro (upstairs off the Mezzanine)
14:30-17:30	ISPOR Health Science Policy Council	Morar-Ness (Seminar Suite)
15:30-17:30	ISPOR HTA Roundtable - Middle East and Africa	Gallery Bistro (upstairs off the Mezzanine)
16:00-17:30	ISPOR Health Science Policy Council Breakout	Katrine (Seminar Suite)
17:45-18:45	ISPOR Africa Network Executive Committee	Leven (Seminar Suite)

MONDAY, 6 NOVEMBER

12:15-14:15 Lu	unch for delegates served in the Exhibit Poster Hall	
7:15-8:15	ISPOR Value & Outcomes Spotlight Editorial Board	Carron (Loch Suite)
7:30-8:30	ISPOR Statistical Methods in Health Economics and Outcomes Research Special Interest Group	Morar-Ness (Seminar Suite)
7:30-8:30	ISPOR Asia Consortium Business Meeting	Alsh (Loch Suite)
12:00-13:45	ISPOR Health State Utility Estimates in CE Models Task Force	Katrine (Seminar Suite)
12:00-14:00	ISPOR Institutional Council Lunch	Leven (Seminar Suite)
12:15-14:00	ISPOR Value in Health Editorial Board and Editorial Advisory Board	Morar-Ness (Seminar Suite)
12:30-13:45	ISPOR CEE Consortium Working Committees: Research, Education, Publication	Dochart (Loch Suite)
12:30-17:00	ISPOR Patient Representatives Roundtable	Gallery Bistro (upstairs off the Mezzanine)
13:45-15:15	ISPOR Expert Elicitation Task Force	Katrine (Seminar Suite)
14:00-15:00	ISPOR Arabic Network Executive Committee	Carron (Loch Suite)
14:15-15:15	ISPOR Poland Chapter	Morar-Ness (Seminar Suite)
15:00-16:00	ISPOR Global Engagement Council	Leven (Seminar Suite)
14:30-16:00	ISPOR Chapters of the Eurasian Economic Union Countries Joint Meeting	Dochart (Loch Suite)
14:30-16:00	ISPOR Greece Chapter	Boisdale (Loch Suite)
15:15-16:45	ISPOR Proposed Stated Preference Methods in Decision Making Good Practices Task Force	Katrine (Seminar Suite)
16:30-17:30	ISPOR Hungary Chapter	Boisdale (Loch Suite)
16:30-17:30	ISPOR Past President's Council	Leven (Seminar Suite)
17:00-18:00	ISPOR Portugal Chapter	Morar-Ness (Seminar Suite)

Invitational Group Meetings

TUESDAY, 7 NOVEMBER

12:00-14:00 L	unch for delegates served in the Exhibit Poster Hall		
7:30-10:00	ISPOR HTA Council	Ness (Seminar Suite)	
7:45-8:45	ISPOR Patient-Centered Special Interest Group	Katrine (Seminar Suite)	
8:45-9:45	ISPOR Austria Chapter	Alsh (Loch Suite)	
8:45-9:45	ISPOR Italy-Rome Chapter	Dochart (Loch Suite)	
12:00-13:45	ISPOR Optimization Task Force	Katrine (Seminar Suite)	
12:00-14:00	ISPOR Student Network/Faculty Advisor Luncheon	Carron (Loch Suite)	
12:30-13:30	ISPOR HTA Council Working Group - HTA Scoping Paper	Ness (Seminar Suite)	
12:30-14:30	ISPOR CEE Consortium Executive Committee	Dochart (Loch Suite)	
13:45-15:15	ISPOR Value of Information Task Force	Katrine (Seminar Suite)	
14:00-18:00	ISPOR Educational Forum: "Applying Multi-Criteria <i>Gallery Bistro (upstairs off the Mezzanine)</i> Decision Analysis (MCDA) Simple Scoring as Evidence-Based Health Technology Assessment (HTA) specifically for Off-Patent Pharmaceuticals in Emerging Markets" (supported by an educational grant from Abbott)		
14:45-15:45	ISPOR ViHRI CEEWAA Editorial Board & Editorial Advisory Board	Ness (Seminar Suite)	
15:00-16:00	ISPOR Ukraine and Serbia Chapters	Alsh (Loch Suite)	
15:15-16:45	ISPOR Stated Preference Research in EU Working Group	Katrine (Seminar Suite)	
16:15-17:15	ISPOR Spain Chapter	Alsh (Loch Suite)	
16:30-17:45	ISPOR Europe Chapters Presidents and EUPATI	Dochart (Loch Suite)	
19:15-20:00	ISPOR Bulgaria Chapter	Carron (Loch Suite)	

WEDNESDAY, 8 NOVEMBER

12:45-13:45 Lunch for delegates served in the Exhibit Poster Hall

9:00-10:30 ISPOR Russia HTA Chapter

Dochart (Loch Suite)



ISPOR Congress App

Your meeting. Your way. In *your* pocket.

A simple, yet powerful, tool to get the most out of your ISPOR congress experience.



Search: ISPOR

WI-FI NETWORK: ISPORGLASGOW PASSWORD: IQVIA2017

Released Presentations

Looking for presentations from ISPOR Glasgow?

www.ispor.org » 20th Annual European Congress » Released Presentations

Presentations are available online after each session, subject to speaker approval.

Over 85% of presentations are expected to be available!

Research Poster Presentations Overview

Nearly 2200 poster presentations will be on display during the congress in the Poster and Exhibit Hall (Hall 4).

- The poster hall is organized in rows (A-N) and each poster board is numbered accordingly (e.g. A1, L15)
- Each poster presentation has been assigned a specific numbered board location, which is shown next to the poster presentation title. Please note that this is different than the poster code (e.g. PHP1, PCV5), which was assigned to each poster presentation upon acceptance.
- Poster presentation titles and authors, as well as the numbered board location, are available on the <u>myISPORGlasgow.zerista.com</u> web platform and mobile app. This information is also available as a PDF on the ISPOR website.
- An Author index is available in Value in Health 20 (9), which is available near ISPOR registration and online at <u>http://www.ispor.org/valueinhealth_index.asp</u>.
- Poster board numbering is available on the floor plan on page 37 and row locations (by topic) are available in the table below.

POSTER PRESENTATION SESSIONS	POSTER LOCATION	PRESENTER SET UP TIME	POSTER DISPLAY HOURS	AUTHOR DISCUSSION HOUR*	PRESENTER DISMANTLE TIME**		
SESSION I: MONDAY, 6 NOVEMBER							
PCN: CANCER	ROWS A-L	8:30-8:45	8:45-13:45	12:45-13:45	13:45		
PDB: DIABETES/ENDOCRINE DISORDERS	ROWS L-N						
PUK: URINARY/KIDNEY DISORDERS	ROWS N						
SESSION II: MONDAY, 6 NOVEM	SESSION II: MONDAY, 6 NOVEMBER						
PHS: HEALTH SERVICES	ROWS A-F	15:30-15:45	15:45-19:30	18:30-19:30	19:30		
PIH: INDIVIDUAL'S HEALTH	ROWS F-G						
PMS:MUSCULAR-SKELETAL DISORDERS	ROWS G-J						
PSY: SYSTEMIC DISORDERS/CONDITIONS	ROWS J-N						
SESSION III: TUESDAY, 7 NOVEMBER							
PMD: MEDICAL DEVICES/DIAGNOSTICS	ROWS A-F	8:30-8:45	8:45-13:30	12:30-13:30	13:30		
PCV: CARDIOVASCULAR DISORDERS	ROWS F-K						
PGI: GASTROINTESTINAL DISORDERS	ROWS K-L						
PRS: RESPIRATORY-RELATED DISORDERS	ROWS L-N						
SESSION IV: TUESDAY, 7 NOVEM	BER	1		1			
PHP: HEALTH CARE USE & POLICY STUDIES	ROWS A-K	15:15-15:30	15:30-19:15	18:15-19:15	19:15		
PMH: MENTAL HEALTH	ROWS K-L						
PND: NEUROLOGICAL DISORDERS	ROWS L-N						
SESSION V: WEDNESDAY, 8 NOVEMBER							
PRM: RESEARCH ON METHODS	ROWS A-I	8:30-8:45	8:45-14:00	13:00-14:00	14:00		
PIN: INFECTION	ROWS I-M						
PSS: SENSORY SYSTEMS DISORDERS	ROWS M-N						

*Presenters are required to be with their posters during the Poster Author Discussion Hour.

**Posters that are not removed at the scheduled dismantle times will be discarded.



Exhibit Program Overview

Exhibits Viewing

Exhibits will be on view in Hall 4.

Monday, 6 November:	8:30-19:45
Tuesday, 7 November:	8:30-19:15
Wednesday, 8 November:	8:30-14:15



Networking Lounges, Charging Stations, and Internet Stations

Please enjoy the various lounges, charging stations, and internet stations on the Exhibit floor.

New this year!

Business Café Sponsored by Complete HEOR Solutions (CHEORS) **Networking/Charging Lounge** Sponsored by IQVIA

Internet stations are available in the front of Hall 4 at the Poster/Exhibit Look-Up Station. **Internet Access/Wi-Fi** *Sponsored by IQVIA*

Schedule

SUNDAY, 5 NOVEMBER

8:00-18:00 Exhibitor Set Up

MONDAY, 6 NOVEMBER

- 8:30-19:45 Exhibits Viewing
- 10:45-11:15 Coffee Break
- 12:15-14:15 Lunch Sponsored by Health Economics and Outcomes Research Ltd
- 15:15-15:45 Coffee Break Sponsored by Ingress Health
- 18:00-19:45 Exhibitors' Open House Reception Sponsored by Complete HEOR Solutions (CHEORS)

TUESDAY, 7 NOVEMBER

8:30-19:15	Exhibits Viewing	COVAN
9:45-10:15	Coffee Break Sponsored by Covance	cov
12:00-14:00	Lunch Sponsored by BaseCase Management GmbH	
15:00-15:30	Coffee Break	
17:45-19:15	Exhibitors' Wine & Cheese Reception Sponsored by Pharmerit International	



HEORS

IMS Health & Quintiles are now



WEDNESDAY, 8 NOVEMBER

8:30-14:15 Exhibits Viewing

- 9:45-10:00 Coffee Break
- 12:45-14:15 Lunch
- 14:15 Exhibitor Dismantle

EXHIBITORS

ISPOR 20th Annual European Congress The Evolution of Value in Health Care


COMPANY NAME **EXHIBIT LOCATION** Accession 801 Adelphi 301 Advanced Clinical Recruitment 202 Amaris 807 AMICULUM Table #1 **AMPLEXOR Life Sciences** 109 Analysis Group 123 ANALYTICA LASER 703 AplusA 405 AXIS Consulting 505 212 Barrington James BaseCase Management GmbH* 814 BresMed 501 Cardinal Health Specialty Solutions 811 **Cochrane Innovations** Table #8 СЕМКА 407 **Complete HEOR Solutions** (CHEORS)* 812 CONSULTING AT McCANN HEALTH 604 **Context Matters** 313 Costello Medical Consulting 316 Covance* 317 CRA, Charles River Associates 507 Creativ-Ceutical 213 **CRECON Medical Assessment Inc.** 406 Crystallise Ltd Table #2 Curo 806 **Decision Resources Group** 403 Digital Health Outcomes & GMAS 111 Dolon Ltd 118 Dymaxium 116 emedcareers Table #10 EORTC Table #7 Evidence Partners Inc. 119 Evidencia Scientific 808 Evidera* 601 216 Excerpta Medica FACIT.org/FACITtrans 117 GalbraithWight 209

Congress Exhibitors

COMPANY NAME	EXHIBIT LOCATION	
Gareth Lee (G&J Lee Recruitment)	Table #3	
GfK	207	
HealthCore, Inc.*	215	
Health iQ	802	
HEVA Group	221	
HTA Consulting	309	
ICON plc	503	
IGES Group	122	
INC Research/inVentiv	Health 605	
Ingress Health*	304	
institute for Medical Te Assessment (iMTA)	chnology 203	
INTEXO SRL	220	
Ipsos Healthcare	120	
IQVIA*	701	
ISPOR	401	
Journal of Health Econo and Outcomes Researc		
Kantar Health	704	
Lifescience Dynamics	311	
Lightspeed Health	Table #9	
MA Provider Srl	Table #5	
MAESTrO Database	302	
MAP BioPharma	103	
Market Access Transfor	mation 112	
MINERVA Network	408	
Mtech Access	303	
Navigant	506	
NEXTEP	115	
Numerus	218	
Open Health/pH Associ	ates/OAC 105	
Optum	211	
Oxford PharmaGenesis	214	
OXON EPIDEMIOLOGY	810	
PAREXEL International	308	
Patients Direct	110	
Pharmatelligence	315	
Pharmerit International	* 813	
PHARMO Institute	803	

COMPANY NAME EXHIBIT LOO	CATION
PHMR*	201
Pope Woodhead	306
PRA Health Sciences	307
Precision Health Economics (Part of Precision for Value)*	702
Prioritis Ltd	602
PRMA Consulting	404
ProClinical	805
Quantify	210
Regulatory Pharma Net srl	114
Remap Consulting	205
R-Squared Talent Solutions	107
RTI Health Solutions	402
RWS Life Sciences	310
ScHARR, University of Sheffield	314
SEC Recruitment	104
SIRIUS Market Access*	305
STATinMED Research	102
stève consultants	208
Synergus	108
Talentmark Ta	able #6
Taylor & Francis	219
Tolley Health Economics Ltd.	121
TransPerfect	101
TreeAge Software	204
Truven Health Analytics, IBM Watson Health*	502
University of Glasgow	106
Valid Insight	217
ValueMAxess Ltd	312
Vitaccess	804
Wickenstones	206
Wing Tech Inc.	113
Xcenda	603
York Health Economics Consortiun	n 504
ZRx Outcomes Research Inc.	809
* Exhibitors who are also sponsors	

Exhibit/Poster Hall Floor Plan



Nearly 2200 poster presentations will be on display during the congress:

SESSION I: MONDAY, 6 NOVEMBER from 8:45-13:45 SESSION II: MONDAY, 6 NOVEMBER from 15:45-19:30 SESSION III: TUESDAY, 7 NOVEMBER from 8:45-13:30 SESSION IV: TUESDAY, 7 NOVEMBER from 15:30-19:15 SESSION V: WEDNESDAY, 8 NOVEMBER from 8:45-14:00

Exhibits will be on view:

Monday, 6 November from 8:30-19:45 Tuesday, 7 November from 8:30-19:15 Wednesday, 8 November from 8:30-14:15


PPi Healthcare Consulting

Adding global value through local expertise and insight

"Securing optimal market access for any medical technology, regardless of its novelty, is becoming increasingly difficult, requiring strategic planning and a thorough insight of stakeholders' practices and expectations. PPi HC has been providing its clients with such insight and guidance since 2001 and would welcome the opportunity to assist you."

Adam Barak, Managing Director

Completed Country Assignments up to 2017:



Pricing and Reimbursement (P&R) Consulting Services:

- Develop national / international pricing strategy throughout product planning process and post-launch
- Implementing and facilitating P&R submissions and revisions
- Direct stakeholder and secondary research to inform positioning and value demonstration strategies

Market Research Consulting Services:

- Market landscaping and segmentation
- Market access and payer research
- Product positioning, messaging
- Qualitative and quantitative research

Health Economic Consulting Services:

- Develop core and country-tailored value / submission dossiers
- Provide value and clinical evidencegeneration needs including supportive studies design

For further information please contact PPi HC on:

Tel: +44 (0)2380 847891 Email: info@ppi.consulting Web: www.ppi.consulting

ISPOR 20th Annual European Congress

The Evolution of Value in Health Care



Key Information

WiFi and Internet Access

Internet stations are provided in the Exhibit-Poster Hall located in Hall 4.

For the convenience of Congress attendees, Wi-Fi is available in the convention center. Network: ISPORGlasgow // Password: IQVIA2017

Wi-Fi is only intended for checking email and using the congress mobile app, not for downloading files. Connection speeds will vary depending on the volume of users. Internet/Wi-Fi Sponsored by IQVIA

Registration Disclaimer

For security purposes all individuals must be registered and wear the official ISPOR Event Name Badge to gain access to the event, the sessions, the exhibit poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if individual does not have an official ISPOR Event Name Badge. Individuals not wearing a name badge will be directed to registration. Please note that if you lose your name badge and need to have it re-printed you cannot print that at the self-serve station, you will need to visit the registration help desk.

Because of the professional nature of the program, safety and liability reasons; guests and anyone under the age of 18 are not permitted access or to register for the event. This includes access to the event in general, to scientific presentations, and to the exhibit and poster hall

For any ISPOR sponsored social event, guests over the age of 21 are permitted to attend but must have a paid event ticket. Due to insurance and liability no one under 21 will be permitted to attend a social event.

Language Information

All sessions at the ISPOR 20th Annual European Congress are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact meetingsinfo@ispor.org

Presentation Slides/Posters

Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the congress app and at the ISPOR 20th Annual European Congress Released Presentations page at www.ispor.org_during/after the congress, subject to speaker approval

Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 42,000 research papers presented at ISPOR meetings) at http://www.ispor.org/ research_study_digest/index.asp.

The Released Presentations page will feature many of the congress' slide presentations as PDFs. In 2016, more than 80% of the presentations were available to the public during/after the congress. The Released Presentations page is accessible via the congress mobile app and at www.ispor.org » 20th Annual European Congress.

Speaker Information

Upload the final version of your slide presentation in the Speaker Ready Room on the same day of your session!

All speakers are encouraged to use the Speaker Ready Room to preview their slide presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker's Corner by the specified advance deadline and all presentations uploaded/ updated in the Speaker Ready Room 30 minutes prior to the session will be preloaded to the computer in the session room. All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.

A speaker ready room is provided in Fyne (Loch Suite) with the opening hours:

- Sunday, 5 November: 12:00-18:00
- Monday, 6 November: 8:00-18:00
 Tuesday, 7 November: 8:00-18:00
- Wednesday, 8 November: 8:00-15:30

ISPOR Research Presentation Awards

Awards are given for the best research presentations for podiums and posters in the categories of GENERAL, NEW INVESTIGATOR, and STUDENT (up to 3 in each category).

All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the Congress.

Award recipients will be notified by email and recognized on the ISPOR website at the conclusion of the congress.

ISPOR Social Event: A Taste of Scotland TUESDAY, 7 November 19:30-23:30 Merchant Square

Join us for whisky tasting, dinner, and traditional dancing and music.

The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.

Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-tolearn traditional dancing.

Separate registration required. The price is €90 and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment. Registration subject to availability, see the ISPOR Registration desk for details

- If you have pre-registered for the Social Event, your ticket will print out with your name badge. You will need this ticket for entry to the bus/event.
- Buses will depart from the SEC between 19:30 and 20:00 for the 15-minute journey to Merchant Square.
- Return buses will start at 21:00, last bus at 23:15.

Social Media

Communicating by way of social media is encouraged if it falls 💟 in 👖 🛗 within embargo and communications rules.

Be part of the live discussion!

- Tweet your comments to @ISPORorg during the congress using #ISPORGlasgow Access expert insights and share your views on congress sessions at the ISPOR
- LinkedIn Discussion Group: http://bit.ly/ISPOR-LIn
- Network with your peers on the ISPOR Facebook page: http://bit.ly/ISPOR-FB

Recording and Press Information

ISPOR supports the promotion of research presented at ISPOR congresses, while safeguarding sensitive information, data, and research findings that are not yet available to the public. Due to the sensitive nature of data and the particularly preliminary, unpublished research findings, all filming and recording of scientific sessions and the poster hall is prohibited during the congress, without the express written consent of ISPOR.

Portions of the ISPOR 20th Annual European Congress may be recorded by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). By participating in the discussions, congress registrants agree that ISPOR may electronically copy, videotape, or audiotape their attendance at and involvement in any program. Registration and attendance at the ISPOR 20th Annual European Congress constitutes an agreement by the registrant to ISPOR's use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR. Congress attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's scientific results. Members of the press must identify themselves as such before questioning speakers and congress attendees if using the information in a professional capacity.More detailed information on ISPOR's Press Pass, Legal, and Embargo Policies are available on ISPOR's News & Press page at the ISPOR website (www.ispor.org).

For further questions on these policies, please contact: Betsy Lane (blane@ispor.org), Director and Chief Marketing & Communications Officer.

Congress Program Disclaimer

Please be advised that while the congress program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

Antitrust Compliance

It is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

Financial Disclosure Information

Research podium and poster presentation financial disclosure information is available online at: <u>http://www.ispor.org/valueinhealth_index.asp</u> and in the October/November 2017 issue of *Value in Health*. Faculty and staff involved in the planning or presentation of this congress are required to disclose all real or apparent commercial financial affiliations related to congress content. This information is available on request at the ISPOR Registration desk.

Questions & Information

Please ask ISPOR staff members for any additional information about the congress or about ISPOR. ISPOR staff can be identified by their ISPOR name badge.

